EP1141311A1 - Antigene protecteur de streptococci de groupe a (spa) - Google Patents

Antigene protecteur de streptococci de groupe a (spa)

Info

Publication number
EP1141311A1
EP1141311A1 EP99967585A EP99967585A EP1141311A1 EP 1141311 A1 EP1141311 A1 EP 1141311A1 EP 99967585 A EP99967585 A EP 99967585A EP 99967585 A EP99967585 A EP 99967585A EP 1141311 A1 EP1141311 A1 EP 1141311A1
Authority
EP
European Patent Office
Prior art keywords
spa
polypeptide
isolated
seq
nucleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP99967585A
Other languages
German (de)
English (en)
Inventor
James Dale
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Tennessee Research Foundation
Original Assignee
University of Tennessee Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Tennessee Research Foundation filed Critical University of Tennessee Research Foundation
Publication of EP1141311A1 publication Critical patent/EP1141311A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Definitions

  • the present invention relates to Streptococcal antigens, more particularly to polypeptide antigens and to nucleic acids encoding the same, which are useful for eliciting opsonic antibodies in an animal that are protective against infection by group A streptococci.
  • M protein is an alpha- helical, coiled-coil molecule that extends from the surface with its hypervariable N- terminus exposed to the outside and the conserved C-terminus buried in the cytoplasm.
  • the N-terminus contains type-specific epitopes that evoke bactericidal antibodies that correlate with protection against the homologous serotype.
  • the emm gene is located in a regulon that is controlled by the upstream positive regulator mga.
  • the regulon may contain one, two or three emm and emm-like genes.
  • serotypes containing only one emm gene deletion or interruption of the emm gene results in an avirulent organism that can no longer resist phagocytosis.
  • serotypes that express several emm-like genes each may partially contribute to resistance to phagocytosis, but among the many defined surface proteins of group A Streptococci, only antibodies against the M protein have been shown to be opsonic.
  • Type 18 Streptococci have been identified as an important serotype in the resurgence of acute rheumatic fever in Utah.
  • Types 3 and 18, and to a lesser extent Type 28 Streptococci have all been implicated in the recent resurgence of serious Streptococcal diseases.
  • Each of these diseases could be potentially be prevented by vaccination with an antigen other than M protein, which is capable of eliciting a protective response across divergent serotypes.
  • group A streptococci express surface polypeptides or proteins containing opsonic epitopes not related to M protein.
  • Providing polypeptides from Streptococci containing non-M protein antigens, especially those that have opsonic epitopes would enhance therapeutic tools available to protect against a variety of Streptococcal infections.
  • the present invention provides the discovery of a novel protective antigen isolated from a Streptococcus species that is distinct from M protein and that elicits opsonic antibodies that are effective against multiple serotypes of Streptococci.
  • the novel antigen is a surface antigen of a group A Streptococci, which is herein designated as Spa (Streptococcal protective antigen).
  • the invention provides Spa polypeptides isolated from a Streptococcus species comprising a polypeptide having at least 50% amino acid sequence identity to SEQ. ID NO:2 or 5.
  • the Spa polypeptides are from a streptococcus which is a member of the species Streptococcus pyogenes (group A streptococci).
  • Another embodiment includes an isolated Spa polypeptide from a group A, Type 18 Streptococci serotype.
  • Still another embodiment is a Spa polypeptide comprising the amino acid sequence of SEQ. ID NOS: 2 or 5.
  • Variants of this embodiment include amino acid sequences having conservative amino acid substitutions or those having at least 90% sequence identity to SEQ. ID NOS: 2 or 5.
  • the invention provides any of the aforementioned isolated Spa polypeptides containing an opsonic epitope.
  • the isolated polypeptides contain an opsonic epitope comprised of contiguous amino acids from a portion of an N-terminus of the polypeptide that is exposed on an outside surface of a cell when the polypeptide is expressed in the cell.
  • the isolated Spa polypeptide contains an opsonic epitope comprised of at least 8 contiguous amino acids of the N-terminus of the polypeptide.
  • the isolated Spa polypeptide contains an opsonic epitope comprised of at least 23 contiguous amino acids of the N-terminus of the polypeptide of SEQ. ID NOS: 2 or 5 or polypeptides having at least 50% identity thereto.
  • the isolated Spa polypeptide includes the peptide of SEQ. ID NO: 3 or variants thereof that contain an opsonic epitope.
  • the invention provides an immunogen for protecting an animal against a Streptococcus infection where the immunogen is comprised of any of the aforementioned Spa polypeptides.
  • the immunogen for protecting an animal against a Streptococcus infection comprising a peptide that includes at least 8 contiguous amino acids from an N terminus of the aforementioned Spa polypeptides.
  • Another embodiment provides an immunogen comprised of a peptide that includes at least 23 contiguous amino acids from an N terminus of the Spa polypeptide of SEQ. ID NOS: 2 or 5 or polypeptides having at least 50%) identity thereto.
  • the immunogen includes the peptide of SEQ.
  • the aforementioned immunogens are linked to a carrier protein or provided as a fusion protein. Another aspect of any of aforementioned immunogens are that they provides cross-protection against multiple serotypes of Streptococci. In one embodiment the immunogens provide protection against serotypes of Streptococci which are group A serotypes. In another embodiment, the serotypes are selected from Type 3, Type 18 and Type 28 Streptococci.
  • this invention provide antibodies that specifically bind to an epitope present on the aforementioned Spa polypeptides.
  • One embodiment includes antibodies that bind to an epitope comprised of at least 8 contiguous amino acids of the N-terminus of the Spa polypeptide.
  • Another embodiment includes antibodies that bind to an epitope comprised of at least 23 contiguous amino acids of the N-terminus of the Spa polypeptide.
  • the antibodies bind to a peptide according to SEQ. ID NO: 3 or variants thereof that contain an opsonic epitope.
  • the invention provides the aforementioned antibodies which do not bind to an M protein of Streptococcus species.
  • the invention provides an isolated nucleic acid molecule comprising a sequence that encodes the aforementioned Streptococcus Spa polypeptides or a complement of said nucleic acid molecule.
  • the isolated nucleic acid molecule is comprised of a sequence selected from SEQ. ID NOS: 1, or 4, or 5 a complement or variants thereof.
  • Variants of the nucleic acid sequences include variants selected from sequences that encode the polypeptide of SEQ. ID NOS: 2 or 5 which are degenerate to SEQ. ID NOS: 1 or 4 because of the genetic code; sequences that encode a polypeptide which has conservative amino acid substitutions to the polypeptide of SEQ.
  • the invention provides an isolated nucleic acid molecule comprising a sequence that hybridizes to the aforementioned nucleic acid molecules under conditions of moderate or high stringency.
  • isolated nucleic acid molecules comprising a sequence that encodes an opsonic epitope form a Spa polypeptide comprising a polypeptide having at least 50%> amino acid sequence identity to SEQ. ID NOS:2 or 5.
  • nucleic acid sequences provided herein include nucleic acid molecules encoding an opsonic epitope and further encoding a fusion polypeptide wherein the fusion polypeptide contains the opsonic epitope fused to at least one other peptide sequence.
  • the other peptide sequence includes a tag sequence that facilitates isolation of the fusion polypeptide from a cellular extract.
  • the other peptide sequence is a carrier protein.
  • a related embodiment to the aforementioned nucleic acid molecules includes a vector comprising those nucleic acid molecules operably linked to a promoter so that the vector expresses a polypeptide encoded by the isolated nucleic acid when the vector is introduced into a host cell.
  • the invention provides a host cell carrying such a vector.
  • a fifth aspect of this invention provides a therapeutic composition for protecting an animal from a Streptococcus infection comprising a biologically acceptable diluent and an effective amount of a an immunizing agent selected from the aforementioned polypeptides, peptides, immunogens, host cells and antibodies.
  • the therapeutic composition may include: a) a Spa polypeptide isolated from Streptococcus; b) an immunogen comprised of an opsonic epitope obtained from the Spa polypeptide; c) a host cell that expresses an opsonic epitope obtained from the Spa polypeptide; or d) an antibody that specifically binds to the Spa polypeptide.
  • the aforementioned immunizing agents may be conjugated to a polyvalent carrier.
  • a sixth related aspect of this invention includes a therapeutic method for protecting an animal against a Streptococcus infection comprising the step of administering to the animal the aforementioned therapeutic compositions wherein administering the therapeutic compositions elicits opsonic antibodies in the animal.
  • protection is provided against multiple serotypes of Streptococcus.
  • the therapeutic composition is administered by at least one of oral administration, intranasal administration, parenteral (intramuscular, subcutaneous, or intravenous) vaccination.
  • the therapeutic method is provided when the animal is a human.
  • the present invention provides diagnostic compositions and methods for detecting infection by a Streptococcus species in a target sample.
  • primers derived from the nucleotide sequence of a Spa gene are used to amplify nucleic acids extracted from cells obtained from target sample.
  • the extracted nucleic acid is DNA.
  • the extracted nucleic acids contains mRNA.
  • diagnosis is performed by detecting a nucleic acid sequence amplified by PCR using primers provided in SEQ. ID NOS: 4 and 5.
  • primers are selected from any portion of a Spa gene or compliment thereof containing at least 12 contiguous nucleotides, wherein the primers specifically hybridize to a selected portion of the Spa gene.
  • the invention provides probes useful in the diagnosis of a Streptococcus infection wherein the probes contain at least 12 contiguous nucleotides that specifically hybridize to a selected portion of the Spa gene.
  • the diagnostic compositions and methods of the present invention include antibodies that specifically bind to a Spa polypeptide.
  • the antibodies are opsonic antibodies.
  • the antibodies are polyvalent antibodies while in other embodiments the antibodies are monoclonal antibodies.
  • the antibodies are conjugated to a detectable signaling moiety.
  • the Spa antibodies are used in combination with other immunochemical reagents.
  • the other immunochemical reagents form a complex with the Spa antibodies wherein the complex provides a detectable signal under conditions where a Spa polypeptide is bound to a Spa antibody.
  • the invention provides diagnostic kits comprised of the aforementioned primers, probes or antibodies.
  • the kits further contain reagents for detecting Spa nucleic acids which are amplified or which hybridize to the primers or probes provided herein.
  • the kits contain immunochemical reagents for detecting binding of Spa antibodies to Spa polypeptides isolated from a target sample.
  • Figure 1 depicts a Western blot analysis of whole-cell extracts of Ml 8 (lanes A, C, and E) and M18 ⁇ (lanes B, D, and F) reacted with rabbit antisera against rM18 (lanes A and B), SMI 8(1 -30) (lanes C and D), and SM5(265-291) (lanes E and F).
  • Coomassie blue stained multiple proteins in extracts from both strains (Ml 8, lane G and M18 ⁇ , lane H).
  • Figure 2 illustrates identification of Spa in a crude pepsin extract of M18 ⁇ .
  • the extract was separated by preparative polyacrylamide gel electrophoresis and the entire gel was transferred to nitrocellulose paper.
  • the ends of the paper were cut vertically and stained with Coomassie blue.
  • the center section was cut into horizontal strips approximately 10-12 mm in width and each one is identified as a fraction number. These strips were cut into smaller pieces and used as to absorb opsonic antibodies from a rabbit antiserum against crude pep M18 ⁇ .
  • Opsonization assays were performed using the M18 ⁇ strain, each absorbed antiserum, and antisera inhibited with 1 mg/ml of pep Ml 8 or pep M18 ⁇ . Percent inhibition was based on the level of opsonization achieved with the unabsorbed antiserum.
  • Figure 3 shows polyacrylamide gel electrophoresis of a purified fragment of Spa (lanes A and B) and Western blot analysis of the native protein extracted by phage lysin (lanes C and D).
  • the crude pep M18 ⁇ (lane A) and the purified Spa (lane B) were electrophoresed in a 10%o polyacrylamide gel under reducing conditions and stained with Coomassie blue.
  • the purified Spa migrated with an apparent molecular weight of 24 kDa.
  • Western blot analysis was performed to identify the native Spa that was released from the cell wall of M18 ⁇ by group C Streptococcal phage-associated lysin.
  • the crude lysin extract contained multiple proteins that stained with Coomassie blue (lane C). Antiserum against the synthetic peptide of Spa reacted with a single protein in the extract with an apparent M.W. of 50kDa (lane D).
  • Figure 4 shows a partial DNA sequence of an isolated spa gene and a deduced amino acid sequence for a Spa polypeptide.
  • the sequence has been submitted to GenBank and has the accession number AF086813.
  • Figure 5 (presented in Figures 5A, 5B and 5C) shows a full length DNA sequence according to SEQ ID NO:4 encoding a Spa polypeptide.
  • a start codon begins at position 145
  • a signal peptide is encoded by positions 145-255
  • a mature protein begins at position 256.
  • Figure 6 shows an amino acid sequence for a full length Spa polypeptide according to SEQ ID NO:5. A signal peptide at positions 1-37 is underlined.
  • Nucleic acid or '"nucleic acid molecule refers to any of deoxyribonucleic acid (DNA), ribonucleic acid (RNA), oligonucleotides, fragments generated by the polymerase chain reaction (PCR), and fragments generated by any of ligation, scission, endonuclease action, and exonuclease action.
  • Nucleic acids can be composed of monomers that are naturally-occurring nucleotides (such as deoxyribonucleotides and ribonucleotides), or analogs of naturally-occurring nucleotides (e.g., ⁇ -enantiomeric forms of naturally-occurring nucleotides), or a combination of both.
  • Modified nucleotides can have modifications in sugar moieties and/or in pyrimidine or purine base moieties.
  • Sugar modifications include, for example, replacement of one or more hydroxyl groups with halogens, alkyl groups, amines, and azido groups, or sugars can be functionalized as ethers or esters.
  • the entire sugar moiety can be replaced with sterically and electronically similar structures, such as aza-sugars and carbocyclic sugar analogs.
  • modifications in a base moiety include alkylated purines and pyrimidines, acylated purines or pyrimidines, or other well-known heterocyclic substitutes. Nucleic acid monomers can be linked by phosphodiester bonds or analogs of such linkages.
  • nucleic acid also includes so-called “peptide nucleic acids,” which comprise naturally-occurring or modified nucleic acid bases attached to a polyamide backbone. Nucleic acids can be either single stranded or double stranded.
  • isolated nucleic acid molecule is a molecule that is not integrated in the genomic DNA of an organism.
  • a DNA molecule that encodes a Spa polypeptide that has been separated from the genomic DNA of a Streptococcus cell is an isolated DNA molecule.
  • Another example of an isolated nucleic acid molecule is a chemically-synthesized nucleic acid molecule that is not integrated in the genome of an organism.
  • the isolated nucleic acid molecule may be genomic DNA, cDNA, RNA, or composed at least in part of nucleic acid analogs.
  • an "isolated" polypeptide” is a polypeptide that has been removed by at least one step from its original environment.
  • a naturally occurring protein is isolated if it is separated from some or all of the coexisting material in the natural system such as carbohydrate, lipid, or other proteinaceous impurities associated with the polypeptide in nature.
  • a particular protein preparation contains an isolated polypeptide if it appears nominally as a single band on SDS-PAGE gel with Coomassie Blue staining.
  • """Promoter” is a nucleotide sequence that directs the transcription of a structural gene. Typically, a promoter is located in the 5' region of a gene, proximal to the transcriptional start site of a structural gene. If a promoter is an inducible promoter, then the rate of transcription increases in response to an inducing agent. In contrast, the rate of transcription is not regulated by an inducing agent if the promoter is a constitutive promoter.
  • Vector refers to an assembly which is capable of directing the expression of desired protein.
  • the vector must include transcriptional promoter elements which are operably linked to the genes of interest.
  • the vector may be composed of either deoxyribonucleic acids ("DNA”), ribonucleic acids ("RNA”), or a combination of the two (e.g., a DNA-RNA chimeric).
  • the vector may include a polyadenylation sequence, one or more restriction sites, as well as one or more selectable markers such as neomycin phosphotransferase or hygromycin phosphotransferase.
  • other genetic elements such as an origin of replication, additional nucleic acid restriction sites, enhancers, sequences conferring inducibility of transcription, and selectable markers, may also be incorporated into the vectors described herein.
  • Cloning vector refers to nucleic acid molecules, such as a plasmid, cosmid, or bacteriophage, that has the capability of replicating autonomously in a host cell.
  • Cloning vectors typically contain one or a small number of restriction endonuclease recognition sites at which foreign nucleotide sequences can be inserted in a determinable fashion without loss of an essential biological function of the vector, as well as nucleotide sequences encoding a marker gene that is suitable for use in the identification and selection of cells transformed with the cloning vector. Marker genes typically include genes that provide tetracycline resistance or ampicillin resistance.
  • “Expression vector” refers to a nucleic acid molecule encoding a gene that is expressed in a host cell. Typically, gene expression is placed under the control of a promoter, and optionally, under the control of at least one regulatory element. Such a gene is said to be “operably linked to” the promoter. Similarly, a regulatory element and a promoter are operably linked if the regulatory element modulates the activity of the promoter.
  • Recombinant host refers to any prokaryotic or eukaryotic cell that contains either a cloning vector or expression vector. This term also includes those prokaryotic or eukaryotic cells that have been genetically engineered to contain the cloned gene(s) in the chromosome or genome of the host cell.
  • RNA polymerase II catalyzes the transcription of a structural gene to produce mRNA.
  • a nucleic acid molecule can be designed to contain an RNA polymerase II template in which the RNA transcript has a sequence that is complementary to that of a specific mRNA.
  • the RNA transcript is termed an "anti- sense RNA” and a nucleic acid molecule that encodes the anti-sense RNA is termed an "anti-sense gene.”
  • Anti-sense RNA molecules are capable of binding to mRNA molecules, resulting in an inhibition of mRNA translation.
  • Mode or stringent hybridization conditions are conditions of hybridization of a probe nucleotide sequence to a target nucleotide sequence wherein hybridization will only be readily detectable when a portion of the target sequence is substantially similar to the complement of the probe sequence.
  • Hybridization conditions vary with probe size as well as with temperature, time and salt concentration in a manner known to those of ordinary skill in the art.
  • 5xSSPE 180 mM sodium chloride, 10 mM sodium phosphate, 1 mM EDTA (pH 7.7)
  • 5xDenhardt's solution 2% (w/v) bovine serum albumin, 2% (w/v) Ficoll, 2% (w/v) polyvinylpyrrolidone) and 0.5%) SDS incubated overnight at 55-60°C.
  • Stringent hybridization conditions typically would include 2x SSPE overnight at 42°C, in the presence of 50%> formamide followed by one or more washes in 0.1-0.2x SSC and 0.1 % SDS at 65°C for 30 minutes or more.
  • Percent identity or “%> identity” with reference to a subject polypeptide or peptide sequence is the percentage value returned by comparing the whole of the subject polypeptide sequence to a test sequence using a computer implemented algorithm, typically with default parameters. Sequence comparisons can be performed using any standard software program such as BLAST, tBLAST or MEGALIGN mentioned above Still others include those provided in the LASERGENE bioinformatics computing suite, which is produced by DNASTAR (Madison, Wisconsin). Reference for algorithms such as ALIGN or BLAST may be found for example, in Altschul, J Mol. Biol. 219:555-565, 1991; Henikoff and Henikoff, Proc. Natl. Acad. Sci.
  • BLAST is available at the NCBI website (http://wvvWncbi.nlm.nih.gov/cgi-bin/BLAST).
  • Other methods for comparing two nucleotide or amino acid sequences by determining optimal alignment are well-known to those of skill in the art (see, for example, Peruski and Peruski, 77ze Internet and the New Biology . Tools for Genomic and Molecular Research (ASM Press, Inc. 1997), Wu et al. (eds.), "Information Superhighway and Computer Databases of Nucleic Acids and Proteins," in Methods in Gene Biotechnology, pages 123-151 (CRC Press, Inc. 1997), and Bishop (ed.), Guide to Human Genome Computing, 2nd Edition (Academic Press, Inc. 1998)).
  • Spa or “Spa polypeptide” should be understood to include any polypeptide, or nucleic acid encoding a polypeptide having at least 50%>, 60%, 70%>, 80%), 90%), or 95%> amino acid identity to the polypeptides provided herein as SEQ ID NO:2, or 5.
  • Specifically binds means an antibody is able to selectively bind a peptide encoded by a spa gene of this invention.
  • Such an antibody generally associates with a Spa polypeptide with an affinity constant (K a ) of at least 10 4 , preferably at least 10 ⁇ more preferably at least 10 , still more preferably at least 10 and most preferably at least 10 8 .
  • K a affinity constant
  • Affinity constants may be determined by one of ordinary skill in the art using well known techniques (see Scatchard, Ann. N. Y. Acad. Sci. 57:660-672, 1949).
  • YAC yeast artificial chromosome
  • PCR polymerase chain reaction
  • RT-PCR PCR process in which RNA is first transcribed into DNA at the first step using reverse transcriptase (RT);
  • cDNA any DNA made by copying an RNA sequence into DNA form.
  • This invention provides a novel family of polypeptides isolated from a Streptococci species that are distinct from M protein and which provide antigens that elicit opsonic antibodies in an animal.
  • These novel polypeptides herein designated as Spa (Streptococcal protective antigens)
  • nucleic acid molecules SEQ. ID NOS: 1 and 4
  • SEQ ID NOS:2 encodes a 112 residue polypeptide that is a part of the N-terminus of a mature Spa polypeptide.
  • SEQ. ID NOS: 2 encodes a 112 residue polypeptide that is a part of the N-terminus of a mature Spa polypeptide.
  • a 23 amino acid peptide sequence SEQ.
  • SEQ ID NO: 3 comprising a portion of an N-terminus of a Spa polypeptide which contains an opsonic epitope.
  • the polypeptides of SEQ. ID NOS: 2 and 3 are therefore part of a larger protein of about 50 kD encoded by a Streptococcus gene herein designated as spa.
  • SEQ ID NO:4 is a full-length spa gene encoding the full-length pro-protein of SEQ ID NO:5.
  • SEQ ID NOS: 2 and 3 are part of the mature protein and corresponds to position 44 of SEQ ID NO:5.
  • the invention also encompasses variants of the nucleic acid represented by SEQ. ID NOS: 1 and 4, and the polypeptides represented by SEQ. ID NOS: 2, 3 or 5 which are further described hereafter.
  • Vectors and host cells carrying nucleic acids encoding Spa or opsonic epitopes of Spa are also provided by the present invention.
  • the invention further includes immunogens comprised of Spa polypeptides and/or peptides comprised of contiguous amino acids from the N-terminus of a Spa polypeptide.
  • antibodies that specifically bind to a Spa polypeptide or to antigens contained therein are also included in this invention.
  • the polypeptides, antigens, host cells expressing opsonic epitopes and antibodies that specifically bind thereto can each serve as immunizing agents in therapeutic compositions for protecting an animal from infection by multiple serotypes of Streptococci. Accordingly, this invention further encompasses such therapeutic compositions and methods of their use to protect an animal against a Streptococcus infection.
  • an "opsonic epitope” is that peptide or polypeptide portion of a protein which forms an antigen that elicits the production of, and binds to, opsonic antibodies evoked by immunizing an animal with a host cell containing the antigen.
  • a "surface protein” is protein having a portion of its amino acid sequence displayed on the outer surface of a host cell which contains the protein.
  • Opsonic antibodies has the meaning commonly understood by those of ordinary skill in the art as antibodies which facilitates phagocytic activity against a particle, such as a host cell, that contains the antigen.
  • One way to produce an M-negative mutant is by inactivation of an emm gene encoding an M protein in a Streptococcal strain. Suitable strains include any pathogenic Streptococci. In one embodiment of this invention, a group A Type 18 Streptococcus (designated Ml 8) is used. Many methods are known in the art for inactivation of a bacterial gene are suitable for the practice of this invention. In one method exemplified herein, a ⁇ interposon element is introduced into the chromosome of a Streptococcal species to inactivate an emm gene present in a Type 18 Streptococcus serotype (emm 18).
  • One way to accomplished this is to first ligate a ⁇ interposon element into the coding sequence of an emm 18 gene that has been cloned into a first vector so as to obtain a second vector containing an emm 18 which is inactivated by insertion of the ⁇ element.
  • This second vector is then used to transform a parent strain so that the inactivated emm 18 recombines with and replaces the native emm 18 gene present on the chromosome of the parent strain.
  • Insertionally inactivated strains can be screened for the presence of the inactivated emm 18 gene by southern blotting using the ⁇ interposon element as a probe in combination with a probe for the emm 18 gene. Inactivation of the emm 18 gene can be confirmed by showing absence of expressed M protein by any method for detecting the protein such as for example, immunoblotting an extract using an antibody specific for the M protein.
  • Figure 1 illustrates western blotting to determine the absence of expressed M protein in one M negative mutant (M18 ⁇ , described hereafter) using antisera prepared against a each of; a native M protein (rM18) from a Type 18 Streptococcus; a 30 amino acid N-terminal peptide of the Ml 8 protein, (SMI 8(1 -30); and an internal fragment from a Type 5 Streptococcus M protein (SM5(265-291). (see also Example 1).
  • An M-negative Streptococcus mutant suitable for identifying a Spa antigen preferably exhibits continued virulence in a mammalian system because non-virulent strains are less likely to elicit opsonic antibodies. Virulence of an M-negative mutant may be tested by several methods known in the art. One method is grow the strain in mammalian blood and to score virulence by the number of generations of growth obtained in the blood culture. Typically, a virulent strain will grow for at least 4 generations after three hours of culture in mammalian blood.
  • a test for virulence in blood uses blood obtained from an animal for which protection against Streptococcal infection is sought.
  • an Ml 8 parent strain used to produce the M-negative mutant M18 ⁇ grew for 8 generations after a three hour rotation in human blood.
  • the M18 ⁇ mutant showed similar virulence by growing for 7.5 generations under the same conditions. (See Example 1).
  • Another method for assessing virulence is by an intraperitoneal challenge infection. Briefly, this method determines the does of bacterial particles necessary to be lethal in a test animal, usually a mouse. Virulence is scored by calculating the number of bacteria that is lethal to 50%> of test animals after intraperitoneal injection (LD50). Typically, a virulent strain will have an LD50 of less than 10 6 in a mouse. For example, the Ml 8 parent strain discussed above had an LD50 of 0.73 x 10 5 while the M18 ⁇ mutant had an LD50 of 1.26 x 10 5 .
  • the lethality of the mutant bacteria can be confirmed by recovering live bacteria from the spleens of test animals which succumb to the injection and testing for the presence of identifying characteristics of the mutant, such as for example, drug resistance or maintenance of the M-negative phenotype.
  • the presence of a Spa polypeptide can be initially assessed by scoring for the presence of opsonizing epitopes on the surface of the mutant bacteria.
  • the ordinarily skilled artisan will recognize a variety of in vivo and in vitro methods of testing for the presence of opsonizing epitopes.
  • One method is to raise antisera against a crude surface peptide fraction (pep) released from the surface of bacterial particles after treating bacterial particles with a protease, and then to use the antisera in an in-vitro opsonization assay.
  • proteases are known in the art are suitable for the preparation of a crude surface peptide fraction from the surface of bacteria.
  • a protease which cleaves many different peptide linkages such as for example pepsin
  • a protease which cleaves many different peptide linkages such as for example pepsin
  • a bacterial particles under reaction conditions that are suboptimal for the activity of the protease and/or with an amount of protease selected to yield a mixture enriched with larger rather than smaller polypeptides.
  • Guidance for reaction conditions useful for releasing surface peptides from Streptococci particles may be found in part by the disclosure provided herein. (See Examples 3 and 4).
  • Antisera against the crude surface peptide fraction may be raised in several species, typically mammals and, most typically rabbits.
  • An example in vitro opsonization assay useful in the practice of this invention is an opsonophagocytosis assay which detects phagocytosis facilitated by the presence of opsonizing antibodies present in a test antisera. Briefly, the assay measures the amount of phagocytosis of selected bacterial particles after preincubating the particles in the presence or absence of antisera raised against a sample of antigens obtained from the test bacteria. Preincubation with the antisera coats the particles with reactive antibodies, some of which will be opsonic antibodies elicited from opsonic epitopes present on the surface of the bacterial particles.
  • Preincubated coated particles are then mixed with whole blood from an animal, typically a mammal for which opsonic protection is to be sought (e.g., a human) to determine the percentage of neutrophils that associate with the bacterial particles which is a measure of phagocytic activity facilitated by opsonic antibodies.
  • Antisera containing opsonic antibodies induce a higher percentage of neutrophils associated with the selected bacteria than does antisera lacking opsonic antibodies.
  • the bactericidal activity of antisera can be tested by incubating the antisera with fewer bacterial particles, incubating in blood for a longer period of time and then plating the mixture on a culture medium to score for viable bacteria.
  • the presence of opsonic antibodies in the antisera increase the number of bacteria destroyed by phagocytosis and therefore lowers the number of colony forming units (CFUs) detected on the plate culture.
  • CFUs colony forming units
  • bacteria particles can be selected to score for serotype and strain specificity of opsonic epitopes.
  • antisera raised against crude surface peptides obtained from one serotype may be tested for the ability to provide opsonic protection against other serotypes by scoring for opsonophagocytosis or bactericidal activity against the other serotypes.
  • the presence of a novel opsonic polypeptide, such as the Spa antigen of the present invention can be detected by comparing the ability of different antisera raised against different surface antigen preparations to provide opsonic protection against different strains.
  • antisera raised against crude surface peptides obtained from the Ml 8 parent strain provided opsonic protection against both the parent and the M18 ⁇ mutant, however, antisera raised against purified M protein of the parent (Ml 8 protein) or an N-terminal fragment thereof only provided protection against the parent and not the mutant strain.
  • M protein of the parent Ml 8 protein
  • N-terminal fragment thereof only provided protection against the parent and not the mutant strain.
  • opsonic protection was provided against at least three serotypes of group A Streptococci including Type 3, Type 18 and Type 28. This indicates the mutant displays a novel opsonic epitope other than M protein which is capable of providing opsonic protection across multiple Streptococci serotypes.
  • the parent, the mutant and other serotypes display the novel opsonic epitope (Spa) this epitope is readily shown to be distinct from M protein by showing the M negative mutant expressed the epitope even while M protein is not expressed.
  • Identification of a virulent, M-negative Streptococcus mutant provides a first step in a general method for the identification and isolation of the Spa polypeptides and antigens of the present invention.
  • the surface polypeptide to be separated is comprised of the crude surface peptide mixture obtained by protease treatment of an M-negative Streptococcus mutant shown to display an opsonic epitope other than M protein.
  • separation is performed to isolate the Spa polypeptide from other peptides present in the crude surface peptide mixture.
  • One skilled in the art is able to envision numerous protocols for separating a crude surface peptide mixture including but not limited to a wide spectrum of electrophoresis and chromatography techniques particularly designed for separating polypeptides.
  • a combination of polyacrylamide gel electrophoresis, antibody binding and opsonization inhibition assays are used to separate and identify Spa polypeptides containing opsonic epitopes.
  • An example of use of this protocol is illustrated in Figure 2. Briefly, a crude surface peptide mixture is separated on a preparative 10%> SDS polyacrylamide gel and then immunoblotted onto nitrocellulose paper or other suitable blotting substrate. The nitrocellulose paper is cut into strips containing different fractions of the separated polypeptides and incubated with antisera prepared against the crude surface peptide mixture to absorb antibodies that bind to the separated polypeptides.
  • the absorbed antisera are then used in an opsonization assay and compared to the results obtained with unabsorbed antisera.
  • Opsonic polypeptides present on the nitrocellulose strips will absorb opsonic antibodies from the test antisera so that the residual antisera will show reduced activity (inhibition) in an opsonization assay in comparison to unabsorbed antisera.
  • a duplicate immunoblot is subjected to ordinary western blotting to confirm the presence of immunoreactive polypeptides.
  • a duplicate polyacrylamide gel can be prepared to aid in purification of polypeptides shown to contain opsonic epitopes by the opsonizations inhibition assays
  • the identified Spa polypeptide is isolated and purified by any polypeptide purification techniques known in the art.
  • to "isolate” means to take any step to separate a species from a milieu in which it naturally occurs, and to “purify” means to isolate a fraction wherein the desired species represents 50%>-100% of all extracted polypeptides present in the fraction.
  • the Spa polypeptide comprise at least 90%> and more preferably at least 95% of polypeptides in the purified fraction.
  • Typical isolation steps useful in the practice of this invention include, but are not limited to, ammonium sulfate precipitation, polyacrylamide gel electrophoresis and HPLC. These techniques are suitable to provide a Spa polypeptide of sufficient quantity and purity to obtain an N-terminal sequence and to raise specific antibodies in a mammal such as a rabbit.
  • a Spa polypeptide present in an group A, Type 18 Streptococcus was identified and purified using the aforementioned protocols with antisera obtained from the M18 ⁇ mutant described above.
  • the polypeptide was purified from a crude surface peptide fraction obtained from the mutant by using precipitation in 60%> saturated ammonium sulfate, followed by dialysis, lyophilization, and preparative polyacrylamide gel electrophoresis.
  • Figure 3(A,B) shows that the isolated polypeptide is estimated to have a size of 24 kD as determined by analytical polyacrylamide gel electrophoresis.
  • Figure 3(C,D) shows a western blot analysis of native proteins released from the cell wall of M18 ⁇ by phage associated lysin C and illustrates that the 24 kD Spa polypeptide is part of a larger native protein having an estimated size of 50 kD.
  • a Spa polypeptide isolated according to the present invention is used to identify and isolate peptide antigens containing opsonic epitopes comprised of contiguous amino acids present on the N-terminus of a Spa polypeptide.
  • contiguous amino acids is a sequence of amino acids which are identical to, or conservative variants of, a precise sequence of amino acids present on a Spa polypeptide.
  • the Spa polypeptides of the present invention are isolated from a cell that expresses the polypeptide and which has a portion of the amino acid sequence of the polypeptide exposed on the outside surface of the cell.
  • “Exposed on the outer surface” means the polypeptide has a portion extended through the outer membrane of the cell which is accessible to a proteases and/or to interaction with the major histocompatibility complex of an animal without having to rupture the cell.
  • the "N- terminus” is a sequence of about 240 amino acids or less that is present at or near the N terminal of a polypeptide that can be obtained after proteolytic cleavage of polypeptides exposed on the surface of a cell. Therefore, the term includes an N-terminus of a proteolytic fragment as well as an N-terminus of a native protein when the N-terminus of the native protein is exposed on the outer surface of a cell.
  • an epitope may consist of peptide sequence as small as 8 amino acids which is generally considered by those skilled in the art to be the lower size limit for a peptide to be capable of forming an epitope that can interact with the major histocompatibility complex (MHC).
  • MHC major histocompatibility complex
  • another aspect of this invention includes polypeptides and peptides containing opsonic epitopes comprised of at least 8 contiguous amino acids from the N-terminus of an isolated Spa polypeptide. Identification of an opsonic amino acid sequence on the Spa polypeptides of the present invention may be accomplished by a variety of methods.
  • One method is to use chemical degradation of Spa to obtain peptide fragments and to test those peptide fragments or to synthetic peptides containing contiguous amino acids derived therefrom, for the presence of opsonic epitopes.
  • Edman degradation of the purified Spa polypeptide is used to provide a precise amino acid sequence for the N-terminus of the isolated polypeptide.
  • Edman degradation is used to provide a precise amino acid sequence of an internal fragment prepared by enzymatic or chemical digestion of the isolated polypeptide.
  • Edman degradation of the Spa polypeptide isolated from the M18 ⁇ mutant described above provided two amino acid sequences: a first sequence of 23 amino acids comprising a portion of the N-terminus of the isolated polypeptide and a second sequence of 10 amino acids comprising a portion of an N- terminus of an internal peptide fragment that was isolated after LysC digestion of the polypeptide.
  • the sequence of the 23 amino acid N-terminus is provided in SEQ. ID NO: 3 and shown in Example 4 along with the sequence of the internal fragment. While not wishing to be bound by speculation, it is believed that SEQ. ID NO: 3 represents the N-terminus of the native Spa protein, however, the possibility that the native Spa protein contains additional amino acids at the N-terminus cannot be excluded.
  • a comparison to SEQ ID NO: 5 shows that the native protein is processed from a preprotein by removal of a residue signal sequence.
  • the isolated peptide fragments or sequences can be identified as containing an opsonic epitope by modification of the methods described above for identifying an opsonic polypeptide. The only modification required is use of a separation system suitable for the separation of smaller peptides. High percentage polyacrylamide gels and HPLC techniques are particularly suited for separating smaller peptides and such techniques are readily accessible to those skilled in the art.
  • synthetic peptides can by made which are contiguous with the amino acid sequences deduced by Edman degradation. Therefore, embodiments of the present invention include peptides containing opsonic epitopes comprised of at least 8 contiguous amino acids of a Spa polypeptide.
  • a peptide containing 23 contiguous amino acids of SEQ. ID NO: 3 which represents the N terminus of an isolated Spa polypeptide is chemically synthesized. That peptide, herein designated spal 8( -23) is shown to be opsonic by first chemically coupling it to a suitable carrier such as KLH and using it to raise antisera in rabbits. Another antiserum is made against the intact Spa polypeptide for comparison. These antisera are then used to show cross reactivity with antisera prepared from crude surface peptides obtained from an M-negative mutant such as M18 ⁇ and to further show the presence of opsonic epitopes using the opsonization assays described above.
  • Results demonstrate that the 23 amino acid peptide of the N terminus of the Spa polypeptide contains an opsonic epitope having a similar opsonizing capacity as that obtained from the whole isolated polypeptide and from the crude surface peptide fraction.
  • Western blotting also shows that antisera to the purified protein and the 23 amino acid peptide does not bind to an M protein such as Ml 8.
  • Results further show that the 23 amino acid peptide and isolated Spa polypeptide produce antisera capable of providing opsonic protection against the parent Ml 8 strain, the mutant strain and other serotypes of Streptococcus, while antisera prepared against M protein from the parent strain is only able to provide opsonic protection against the parent strain. (See Examples 5 and 6.)
  • Spa polypeptide While determining a precise amino acid sequence for an isolated Spa polypeptide or peptide epitopes contained therein is a preferred practice of this invention, it is not necessary to structurally define the isolated polypeptide at the sequence level to obtain the Spa polypeptides provided herein.
  • the aforementioned description provides a method useful for isolating Spa polypeptides from any Streptococcus source, particularly from group A Streptococci.
  • a Spa polypeptide is a polypeptide product having particular functional characteristics that fulfill requirements of the method and which are thereby isolated by practice of the method.
  • a Spa polypeptide is a polypeptide product obtained from a Streptococcus species which is displayed on the outer surface of a Streptococcus bacterium, and which contains antigenic epitopes other than the epitopes contained on an M protein. These epitopes represent opsonic antigens that do not cross react with antisera prepared against M-protein and which are capable of providing opsonic protection against multiple serotypes of Streptococci. These characteristics are found in a polypeptide isolated according to the practices described in this invention.
  • this invention provides a method for identifying and isolating a non M protein Spa polypeptide of a Streptococcus species that elicits opsonic antibodies protective against multiple serotypes of Streptococci.
  • the method includes the steps 1 ) producing a virulent mutant of the Streptococcus species that does not express an M protein; 2) obtaining antisera against a crude surface polypeptide fraction obtained from the mutant; 3) determining that the antisera contains opsonic antibodies that do not cross react with M protein and which provide opsonic protection against the mutant; 4) separating polypeptides in the extract to obtain isolated polypeptide fractions; 5) screening the isolated polypeptide fractions with antisera containing opsonic antibodies to identify Spa polypeptides that contain opsonic epitopes; 6) purifying the polypeptide identified as having opsonic epitopes; and 7) testing the purified polypeptides to determine that they elicit opsonic antibodies that are protective against multiple serotypes of Strepto
  • another embodiment of this invention includes Spa polypeptides isolated according to this method.
  • This method enables the isolation of a variety of Spa polypeptides from a variety of Streptococcus species.
  • the Spa polypeptide isolated from an Ml 8 mutant exemplified in one practice of this invention is protective against at least three serotypes of Streptococci (See Example 6)
  • other Spa polypeptides isolated from other Streptococci can be isolated that are protective against other serotypes of Streptococci.
  • Another aspect of the present invention is isolated nucleic acid molecules comprising a sequence that encodes a Streptococcus Spa polypeptide.
  • This aspect of the invention pertains to isolated nucleic sequences encoding a Spa polypeptide (i.e. a spa gene) as well as those sequences readily derived from isolated nucleic molecules such as for example complementary sequences, reverse sequences and complements of reverse of sequences.
  • the isolated nucleic acid molecule is comprised of a sequence selected from SEQ. ID NOS: 1 or 4, a complement of SEQ. ID NOS: 1 or 4 or variants thereof.
  • Variants of the nucleic acid sequences include variants selected from sequences that encode the polypeptide of SEQ. ID NOS: 2 or 5 which are degenerate to SEQ. ID NOS: 1 or 5 because of the genetic code; sequences that encode a polypeptide which has conservative amino acid substitutions to the polypeptide of SEQ. ID NOS: 2 or 5, or sequence that encode a polypeptide that is at least 50%> identical to SEQ. ID NO: 2 or 5.
  • the invention provides an isolated nucleic acid molecule comprising a sequence that hybridizes to the aforementioned nucleic acid molecules under conditions of high stringency.
  • Another embodiment includes isolated nucleic acid molecules comprising a sequence that encodes an opsonic epitope form a Spa polypeptide.
  • a related aspect of the nucleic acid sequences provided herein include nucleic acid molecules encoding an opsonic epitope and further encoding a fusion polypeptide wherein the fusion polypeptide contains the opsonic epitope fused to at least one other polypeptide sequence.
  • the other peptide sequence includes a tag sequence that facilitates isolation of the fusion polypeptide from a cellular extract.
  • the other peptide sequence is a carrier protein.
  • a related embodiment to the aforementioned nucleic acid molecules includes a vector comprising those nucleic acid molecules operably linked to a promoter so that the vector expresses a polypeptide encoded by the isolated nucleic acid when the vector is introduced into a host cell.
  • the invention provides a host cell carrying such a vector.
  • a spa gene is a Streptococcus gene or nucleic acid variant thereof, that encodes at least 100 amino acids of a Spa polypeptide including for example, the isolated nucleic acid of SEQ. ID NOS: 1 or 4, a nucleic acid that encodes a 24kDa Spa polypeptide or a nucleic acid that encodes a native Spa protein of about 50 kDa.
  • a spa gene is set forth in Figure 4, and in SEQ ID NOS:l- 2 which provides a nucleotide and amino acid sequence from one spa gene isolated from a Type 18 Streptococcus.
  • FIG. 5 and 6 shows full-length nucleic acid and amino acid sequences according to SEQ ID NOS: 4 and 5, respectively. These represent full-length spa sequences and that include a signal peptide of 37 residues that is cleaved to produce a mature spa protein, as indicated.
  • a "fragment" of an isolated spa gene includes any nucleic acid sequence comprising at least 12 nucleotides from an isolated spa gene or a variant of least 12 nucleotides that hybridizes to an isolated spa gene under conditions of moderate or high stringency. Such sequences are useful for a variety of purposes including PCR primers for isolating additional spa sequences or variants thereof from other Streptococci. Another typical use is for recombinant expression of a peptide or polypeptide comprised of epitopes present on a native Spa polypeptide.
  • nucleic acid fragments or oligonucleotides useful as probes and primers for identifying or obtaining Spa sequences. More specifically, a nucleic acid fragment or oligonucleotide that comprise at least 12 contiguous nucleotides of SEQ ID NO:l or 4 are particularly useful for hybridization to Spa nucleic acid sequences and/or for primers that can be used to amplify the same. More particular embodiments include nucleic acid fragments or oligonucleotides where the length is at least 18, 24, 30, 50 or greater than 50 nucleotides. Complements of the above sequences are also included.
  • nucleic acid fragments or oligonucleotides of this invention include those that encode a peptide epitope that can be detected, for example, by the ability to specifically bind to a Spa antibody or which can be used to elicit an immune response in an animal.
  • Useful peptide epitopes are those capable of eliciting antibodies that specifically bind to the peptide or polypeptide comprised of the Spa amino acid residues, or that are capable of eliciting a T-cell response to the same.
  • Peptide sequences of 8 or more amino acids are useful in this regard since it is generally understood by those skilled in the art that 8 amino acids is the lower size limit for a peptide to interact with the major histocompatibility complex (MHC).
  • MHC major histocompatibility complex
  • nucleic acid fragments or oligonucleotides encoding at least 10, 15 or 20 amino acids. Accordingly, the present invention provides nucleic acid fragments or oligonucleotides encoding a peptide comprised of at least 8 contiguous amino acids of the sequence according to SEQ ID NO:2, 5 or 5. Particular embodiments of this aspect include nucleic acid fragments or oligonucleotides encoding a peptide comprised of at least 10, 15, or 20 amino acids. Preferred embodiments include nucleic acid fragments wherein the encoded peptide comprises sequences from the N-terminus of a Spa polypeptide, and more particularly, sequences that encode opsonic epitopes.
  • the invention also provides nucleic acids useful for modulating or inhibiting the expression of a Spa polypeptide in a cell. More specifically, the invention provides for ribozymes that cleaves RNA encoding the aforementioned Spa polypeptides and for antisense molecules that bind to such an RNA. This includes nucleic acid molecules comprising a sequence that encodes such a ribozyme or antisense molecule and vectors comprising the same. Particular embodiments include vectors wherein the aforementioned ribozyme or antisense nucleic acid is operably linked to a promoter.
  • Typical embodiments of these vectors are selected from the group consisting of plasmid vectors, phage vectors, herpes simplex viral vectors, adenoviral vectors, adenovirus-associated viral vectors and retroviral vectors. Host cells comprising the above vectors are also included.
  • Ribozymes are provided which are capable of inhibiting expression of Spa RNA.
  • "ribozymes” are intended to include RNA molecules that contain anti-sense sequences for specific recognition, and an RNA-cleaving enzymatic activity. The catalytic strand cleaves a specific site in a target RNA at greater than stoichiometric concentration.
  • ribozymes may be utilized within the context of the present invention, including for example, the hammerhead ribozyme (for example, as described by Forster and Symons, Cell 48:211-220, 1987; Haseloff and Gerlach, Nature 328:596-600, 1988; Walbot and Bruening, Nature 334:196, 1988; Haseloff and Gerlach, Nature 554:585, 1988); the hairpin ribozyme (for example, as described by Haseloff et al., U.S. Patent No. 5,254,678, issued October 19, 1993 and Hempel et al, European Patent Publication No.
  • the hairpin ribozyme for example, as described by Haseloff et al., U.S. Patent No. 5,254,678, issued October 19, 1993 and Hempel et al, European Patent Publication No.
  • Ribozymes of the present invention typically consist of RNA, but may also be composed of DNA, nucleic acid analogs (e.g., phosphorothioates), or chimerics thereof (e.g., DNA/RNA/RNA).
  • Antisense oligonucleotide molecules are provided which specifically inhibit expression of Spa nucleic acid sequences (see generally, Hirashima et al. in Molecular Biology ofRNA.New Perspectives (M. Inouye and B. S. Dudock, eds., 1987 Academic Press, San Diego, p. 401); Oligonucleotides .Antisense Inhibitors of Gene Expression (J.S. Cohen, ed., 1989 MacMillan Press, London); Stein and Cheng, Science 267:1004-1012, 1993; WO 95/10607; U.S. Patent No. 5,359,051 ; WO 92/06693; and EP-A2-612844).
  • such molecules are constructed such that they are complementary to, and able to form Watson-Crick base pairs with, a region of transcribed Spa mRNA sequence.
  • the resultant double-stranded nucleic acid interferes with subsequent processing of the mRNA, thereby preventing protein synthesis (Example 6).
  • any of the aforementioned nucleic acids may- include modified nucleotides.
  • Modified nucleotides can have modifications in sugar moieties and/or in pyrimidine or purine base moieties.
  • Sugar modifications include, for example, replacement of one or more hydroxyl groups with halogens, alkyl groups, amines, and azido groups, or sugars can be functionalized as ethers or esters.
  • the entire sugar moiety can be replaced with sterically and electronically similar structures, such as aza-sugars and carbocyclic sugar analogs.
  • nucleic acid monomers can be linked by phosphodiester bonds or analogs of such linkages. Analogs of phosphodiester linkages include phosphorothioate, phosphorodithioate, phosphoroselenoate, phosphorodiselenoate, phosphoroanilothioate, phosphoranilidate, phosphoramidate, and the like.
  • the term "nucleic acid” also includes so-called “peptide nucleic acids,” which comprise naturally-occurring or modified nucleic acid bases attached to a polyamide backbone. Nucleic acids can be either single stranded or double stranded.
  • spa genes include nucleic acid sequences encoding wild-type/native Spa polypeptides, as well as other variants (including alleles) tBriefly, such variants may result from natural polymorphisms or be synthesized by recombinant methodology or chemical synthesis, and differ from wild-type polypeptides by one or more amino acid substitutions, insertions, deletions, or the like.
  • Variants encompassing conservative amino acid substitutions include, for example, substitutions of one aliphatic amino acid for another, such as He, Val, Leu, or Ala or substitutions of one polar residue for another, such as between Lys and Arg, Glu and Asp, or Gin and Asn.
  • variants having similar physical properties and functional activities such as for example, the ability to elicit and cross react with similar antibodies.
  • Other variants include nucleic acids sequences that encode a polypeptide having at least 50%, 60%, 70%>, 80%>, 90% or 95%> amino acid identity to SEQ ID NO:2, 3 or 5.
  • Preferred embodiments are those having greater than 90%> or 95%> identity with the amino acid sequence of SEQ. ID NOS: 2 or 3 or 5.
  • nucleotide sequence encoding an Spa or a variant may differ from the native sequences presented herein due to codon degeneracies, nucleotide polymorphisms, or nucleotide substitutions, deletions or insertions.
  • isolated nucleic acids While particular embodiments of such isolated nucleic acids are depicted in SEQ ID NOS:l and 4 and Figures 4 and 5, within the context of the present invention, reference to one or more isolated nucleic acids includes variants of these sequences that are substantially similar in that they encode native or non native proteins, polypeptides or peptides with similar structure and function to the Spa polypeptide of SEQ. ID NOS: 2 or 5.
  • the nucleotide sequence is deemed to be "substantially similar” if: (a) the nucleotide sequence is derived from the coding region of a spa gene isolated from a Streptococcus (including, for example, portions of the sequence or allelic variations of the sequences discussed above) and contains a non-M protein epitope with substantially the same ability to elicit opsonic antibodies protective against Streptococci, or (b) the nucleotide sequence is capable of hybridization to the nucleotide sequences of the present invention under high stringency (e.g., capable of selectively hybridizing to nucleotide sequences a spa gene at least 42° C overnight in the presence of salts and/or formamide at least as stringent as 6X SSC and 50%) formamide); or (c) the nucleotide sequences are degenerate (i.e., sequences which code for the same amino acids using a different codon sequences) as a result of the genetic code to the nucle
  • Another aspect of the present invention is the use of isolated spa nucleotide sequences to produce recombinant proteins for immunizing an animal. Therefore, the use of any length of nucleic acid disclosed by the present invention (preferably 24 nucleotides or longer) which encodes a polypeptide or fragment thereof of at least 8 contiguous amino acids which is capable of binding to the major histocompatibility complex and eliciting or enhancing an immunogenic response is contemplated by this invention.
  • Preferred embodiments include polypeptides or fragments thereof that elicit opsonic antibodies. Immunogenic response can be readily tested by known methods such as challenging a mouse or rabbit with polypeptides or fragments of interest and thereafter collecting antisera and determining if the antibody of interest is present.
  • T-cell responses particularly useful for the detection of T-cell responses include proliferation assays, T-cell cytotoxicity assays, assays for delayed hypersensitivity and assays for opsonization such as previously described.
  • proliferation assays T-cell cytotoxicity assays
  • assays for delayed hypersensitivity assays for opsonization
  • many diagnostic tools are available, including for example, testing binding of antigen to antibodies contained in a sample antisera using conventional western blotting, or using enzyme-linked immunoassays with a tag attached to the antigen of interest.
  • the isolated nucleic acids encoding Spa polypeptides according to this invention can be obtained using a variety of methods.
  • a nucleic acid molecule can be obtained from a cDNA or genomic expression library by screening with an antibody or antibodies reactive with a Spa polypeptide (see. e.g., Sambrook et al., Molecular Cloning: A Laboratory Manual, Cold Spring Harbor, 1989; Ausubel et al., Current Protocols in Molecular Biology, Greene Publishing, 1987).
  • random-primed PCR can be employed (see, e.g., Methods in Enzymol. 254:215, 1995).
  • variations of random-primed PCR can also be used, especially when a particular gene or gene family is desired.
  • one of the primers is a random primer and the other is a degenerate primer based on the amino acid sequence or nucleotide sequence encoding a Spa polypeptide.
  • This method is exemplified for example, in Example 7 where a codon degenerate primer designed to bind to a sequence that encodes any one of several variants of a 23 amino acid N terminus of an isolated Spa polypeptide was used to isolate a 346 nucleotide sequence of a spa gene which is depicted in Figure 4 and SEQ. ID NO: 1.
  • nucleic acid molecules that encode a Spa polypeptide can be isolated by using the sequence information provided herein to synthesize a probe which can be labeled, such as with a radioactive label, enzymatic label, protein label, fluorescent label, or the like, and hybridized to a genomic library or a cDNA library constructed in a phage, plasmid, phagemid, or viral vectors designed for replication or expression in selected host cells (see, e.g., Sambrook et al. (supra); Ausubel et al. (supra)).
  • DNA representing RNA or genomic nucleic acid sequence can also be obtained by amplification using sets of primers complementary to 5' and 3' sequences of the isolated nucleic acid sequences provided in SEQ. ID NO: 1 or to variants thereof as described above. For ease of cloning, restriction sites can also be incorporated into the primers.
  • Variants (including alleles) of the isolated spa nucleic acid sequence provided herein can be readily obtained from natural variants (e.g., polymorphisms, mutants and other serotypes) either synthesized or constructed. Many methods have been developed for generating mutants (see generally Sambrook et al. (supra); Ausubel et al. (supra)). Briefly, preferred methods for generating nucleotide substitutions utilize an oligonucleotide that spans the base or bases to be mutated and contains the mutated base or bases. The oligonucleotide is hybridized to complementary single stranded nucleic acid and second strand synthesis is primed from the oligonucleotide. The double-stranded nucleic acid is prepared for transformation into host cells, such as E. coli, other prokaryotes, yeast or other eukaryotes. Standard screening and vector growth protocols are used to identify mutant sequences and obtain high yields.
  • host cells such as E.
  • deletions and/or insertions of spa genes can be constructed by any of a variety of known methods.
  • the gene can be digested with restriction enzymes and/or nucleases and be religated such that sequences are deleted or religated with additional sequence such that an insertion or large substitution is made.
  • a variety of transposons and other insertional elements may be used to make recombinants having deletions and insertions
  • a spa mutant containing a ⁇ insertional element in a spa gene can be made in a manner similar to the making of the M18 ⁇ described above.
  • Other means of generating variant sequences, known in the art, can be employed, for examples see Sambrook et al.
  • the present invention provides isolated or purified Spa polypeptides proteins and peptides as those terms have been previously defined herein.
  • these isolated or purified materials may be obtained from a host cell expressing a recombinant nucleic acid that encodes Spa polypeptides proteins or peptides which may be isolated from the host cell.
  • the Spa polypeptides of the present invention can be purified by a variety of standard methods with or without a protease treatment or polyacrylamide electrophoresis step, and/or may be isolated from organisms other than Streptococci which have been engineered to express an isolated spa nucleic acid.
  • a Spa polypeptide of the present invention can be isolated by, among other methods, culturing suitable host and vector systems to produce a native Spa protein, polypeptide, fusion protein or peptide fusion using recombinant DNA methods (discussed further herein).
  • Spa may be engineered to be exported from the host cell, retained within the host cell, for example within inclusion bodies, or integrated into the surface of host cell as is the case for natural Spa expression in Streptococci.
  • a supernatant from a culture of the host cell can be used to isolate exported Spa polypeptides.
  • Spa polypeptides When integrated into the surface, Spa polypeptides may be obtained by protease treatment to obtain a crude surface peptide fraction as previously described.
  • Spa proteins, fusion peptides and the like can be obtained by a variety of purification procedures. For example, a Spa-containing extract can be applied to a suitable purification matrix such as a Spa antibody bound to a suitable support.
  • Spa polypeptide can also be concentrated using commercially available protein concentration filters, such as an Amicon or Millipore Pellicon ultrafiltration unit, or by vacuum dialysis.
  • an isolated nucleic acid encoding a Spa protein, polypeptide, or peptide can be expressed as a histidine -tagged molecule, permitting purification on a nickel-chelating matrix.
  • other tags may be used, including FLAG and GST.
  • His-tagged proteins may be incubated with thrombin, resulting in cleavage of a recognition sequence between the tag and the Spa polypeptide (e.g., pET vectors from Invitrogen).
  • Spa polypeptide e.g., pET vectors from Invitrogen
  • the expression vector includes transcriptional promoter/enhancer elements operably linked to an isolated nucleic acid molecule encoding a Spa polypeptide.
  • the expression vector may be composed of either deoxyribonucleic acids ("DNA”), ribonucleic acids ("RNA”), or a combination of the two (e.g., a DNA-RNA chimera).
  • the expression vector may include a polyadenylation sequence or one or more restriction sites.
  • other genetic elements such as an origin of replication, additional nucleic acid restriction sites, enhancers, sequences conferring inducibility of transcription, and genes encoding proteins suitable for use as selectable or identifiable markers, may also be incorporated into the expression vectors described herein.
  • the manipulation and expression of spa genes can be accomplished by culturing host cells containing an expression vector capable of expressing the spa genes.
  • Such vectors or vector constructs include either synthetic or cDNA-derived nucleic acid molecules or genomic DNA fragments encoding the Spa polypeptides, which are operably linked to suitable transcriptional or translational regulatory elements.
  • suitable regulatory elements within the expression vector can be derived from a variety of sources, including bacterial, fungal, viral, mammalian, insect, or plant genes. Selection of appropriate regulatory elements is dependent on the host cell chosen, and can be readily accomplished by one of ordinary skill in the art in light of the present specification.
  • regulatory elements include a transcriptional promoter and enhancer or RNA polymerase binding sequence, a transcriptional terminator, and a ribosomal binding sequence, including a translation initiation signal.
  • Nucleic acid molecules that encode any of the Spa protein, polypeptides, or peptides described above can be expressed by a wide variety of prokaryotic and eukaryotic host cells, including bacterial, mammalian, yeast or other fungi, viral, insect, and plant cells. The selection of a host cell may also assist the production of post- transitionally modified Spa polypeptides, depending upon the desires of the user.
  • Bacterial host cells suitable for carrying out the present invention include but are not limited to, numerous strains of E. coli, as well as various strains of M. leprae, M. tuberculosis, M. bovis, B. subtilis, Salmonella typhimurium, and various species within the genera Pseudomonas, Streptomyces, Streptococcus, and Staphylococcus, as well as many other bacterial species well known to one of ordinary skill in the art.
  • Bacterial expression vectors preferably comprise a promoter, which functions in the host cell, one or more selectable phenotypic markers, and a bacterial origin of replication.
  • Representative promoters include the ⁇ -lactamase (penicillinase) and lactose promoter system (see Chang et al., Nature 275:615. 1978), the T7 RNA polymerase promoter (Studier et al., Meth. Enzymol. 755:60-89. 1990), the lambda promoter (Elvin et al., Gene 57:123-126, 1990), the trp promoter (Nichols and Yanofsky, Meth.
  • telomeres suitable for transforming host cells are well known in the art. including among others, pBR322 (see Bolivar et al., Gene 2:95, 1977), the pUC plasmids pUC18, pUC19, pUC1 18, pUC119 (see Messing, Meth.
  • Fungal host cells suitable for carrying out the present invention include, among others, Saccharomyces pombe. Saccharomyces cerevisiae, the genera Pichia or Kluyveromyces and various species of the genus Aspergillus (McKnight et al.. U.S. Patent No. 4,935,349).
  • Suitable expression vectors for yeast and fungi include, among others, YCp50 (ATCC No. 37419) for yeast, and the amdS cloning vector pV3 (Turnbull, Bio/Technology 7:169, 1989), YRp7 (Struhl et al., Proc. Natl. Acad. Sci.
  • promoters for use in yeast include promoters from yeast glycolytic genes (Hitzeman et al., J Biol. Chem. 255:12073-12080, 1980; Alber and Kawasaki, J. Mol. Appl. Genet. 7:419-434, 1982) or alcohol dehydrogenase genes (Young et al., in Genetic Engineering of Microorganisms for Chemicals, Hollaender et al. (eds.), p. 355, Plenum, New York, 1982; Ammerer, Meth. Enzymol. 101:192-201, 1983).
  • useful promoters for fungi vectors include those derived from Aspergillus nidulans glycolytic genes, such as the adh3 promoter (McKnight et al., EMBO J. 4:2093-2099, 1985).
  • the expression units may also include a transcriptional WQ-OO/37648 PCT/US99/30807
  • terminator An example of a suitable terminator is the adh3 terminator (McKnight et al., ibid., 1985).
  • the yeast vectors will generally include a selectable marker, which may be one of any number of genes that exhibit a dominant phenotype for which a phenotypic assay exists to enable transformants to be selected.
  • selectable markers include those that complement host cell auxotrophy, provide antibiotic resistance or enable a cell to utilize specific carbon sources, and include leu2 (Broach et al., ibid.), ura3 (Botstein et al., Gene 5:17, 1979), or his3 (Struhl et al., ibid.).
  • Another suitable selectable marker is the cat gene, which confers chloramphenicol resistance on yeast cells.
  • the genotype of the host cell may contain a genetic defect that is complemented by the selectable marker present on the expression vector. Choice of a particular host and selectable marker is well within the level of ordinary skill in the art in light of the present specification.
  • Transformation may be readily accomplished either by preparation of spheroplasts of yeast with DNA (see Hinnen et al., PNAS USA 75:1929, 1978) or by treatment with alkaline salts such as LiCl (see Itoh et al., J. Bacteriology 755:163, 1983). Transformation of fungi may also be carried out using polyethylene glycol as described by Cullen et al. (Bio/Technology 5:369, 1987).
  • Viral vectors include those that comprise a promoter that directs the expression of an isolated nucleic acid molecule that encodes a Spa polypeptide as described above.
  • a wide variety of promoters may be utilized within the context of the present invention, including for example, promoters such as MoMLV LTR, RSV LTR, Friend MuLV LTR, adenoviral promoter (Ohno et al., Science 265: 781-784, 1994), neomycin phosphotransferase promoter/enhancer, late parvovirus promoter (Koering et al., Hum. Gene Therap.
  • Herpes TK promoter Herpes TK promoter, SV40 promoter, metallothionein Ha gene enhancer/promoter, cytomegalovirus immediate early promoter, and the cytomegalovirus immediate late promoter.
  • the promoter may also be a tissue-specific promoter (see e.g., WO 91/02805; EP 0,415,731 ; and WO 90/07936).
  • viral-specific promoters e.g., retroviral promoters (including those noted above, as well as others such as HIV promoters), hepatitis, herpes (e.g., EBV), and bacterial, fungal or parasitic-specific (e.g., malarial- specific) promoters may be utilized in order to target a specific cell or tissue which is infected with a virus, bacteria, fungus or parasite.
  • retroviral promoters including those noted above, as well as others such as HIV promoters
  • hepatitis e.g., herpes (e.g., EBV)
  • bacterial, fungal or parasitic-specific e.g., malarial- specific
  • Spa polypeptides of the present invention may be expressed from a variety of viral vectors, including for example, herpes viral vectors (e.g., U.S. Patent No. 5.288,641), adenoviral vectors (e.g., WO 94/26914, WO 93/9191 ; Kolls et al, PNAS 91 ( ):215-219, 1994; Kass-Eisler et al., PNAS 90(24): ⁇ 1498-502, 1993; Guzman et al., Circulation 55(6):2838-48, 1993; Guzman et al., Cir. Res.
  • herpes viral vectors e.g., U.S. Patent No. 5.288,641
  • adenoviral vectors e.g., WO 94/26914, WO 93/9191 ; Kolls et al, PNAS 91 ( ):215-219, 1994; Kass-Eisler et
  • retroviruses e.g., ⁇ P 0,415,731 ; WO 90/07936; WO 91/0285, WO 94/03622; WO 93/25698; WO 93/25234; U.S. Patent No. 5,219,740; WO 93/11230; WO 93/10218.
  • the viral vector itself or a viral particle which contains the viral vector may be utilized in the methods and compositions described below.
  • Mammalian cells suitable for carrying out the present invention include, among others: PC12 (ATCC No. CRL1721), N1 ⁇ -115 neuroblastoma, SK-N-BE(2)C neuroblastoma, SHSY5 adrenergic neuroblastoma, NS20Y and NG108-15 murine cholinergic cell lines, or rat F2 dorsal root ganglion line, COS (e.g., ATCC No. CRL 1650 or 1651), BHK (e.g., ATCC No. CRL 6281 ; BHK 570 cell line (deposited with the American Type Culture Collection under accession number CRL 10314), CHO (ATCC No. CCL 61), HeLa (e.g., ATCC No.
  • Rat Hep I ATCC No. CRL 1600
  • Rat Hep II ATCC No. CRL 1548
  • TCMK ATCC No. CCL 139
  • Human lung ATCC No. CCL 75.1
  • Human hepatoma ATCC No. HTB-52
  • Hep G2 ATCC No. HB 8065
  • Mouse liver ATCC No. CCL 29.1
  • NCTC 1469 ATCC No. CCL 9.1
  • SP2/0- Agl4 ATCC No. 1581
  • HIT-T15 ATCC No.
  • Mammalian expression vectors for use in carrying out the present invention include a promoter capable of directing the transcription of a cloned gene or cDNA.
  • Preferred promoters include viral promoters and cellular promoters.
  • Viral promoters include the cytomegalovirus immediate early promoter (Boshart et al., Cell 47:521-530, 1985), cytomegalovirus immediate late promoter, SV40 promoter (Subramani et al., Mol. Cell. Biol. 7:854-864, 1981), MMTV LTR.
  • RSV L TR metallothionein-1
  • adenovirus El a Cellular promoters include the mouse mexallothionein-1 promoter (Palmiter et al., U.S. Patent No. 4,579,821), action promoters, a mouse V H promoter (Bergman et al., Proc. Natl. Acad. Sci. USA 57:7041- 7045, 1983; Grant et al., Nucl. Acids Res. 15:5496, 1987) and a mouse V H promoter (Loh et al., Cell 55:85-93, 1983).
  • the choice of promoter will depend, at least in part, upon the level of expression desired or the recipient cell line to be transfected.
  • Such expression vectors can also contain a set of RNA splice sites located downstream from the promoter and upstream from the DNA sequence encoding the peptide or protein of interest. Preferred RNA splice sites may be obtained from adenovirus and/or immunoglobulin genes. Also contained in the expression vectors is a polyadenylation signal located downstream of the coding sequence of interest. Suitable polyadenylation signals include the early or late polyadenylation signals from SV40 (Kaufman and Sharp, ibid.), the polyadenylation signal from the Adenovirus 5 E1B region and the human growth hormone gene terminator (DeNoto et al., Nuc. Acids Res. 9:3719-3730. 1981).
  • the expression vectors may include a noncoding viral leader sequence, such as the Adenovirus 2 tripartite leader, located between the promoter and the RNA splice sites.
  • Preferred vectors may also include enhancer sequences, such as the SV40 enhancer.
  • Expression vectors may also include sequences encoding the adenovirus VA RNAs. Suitable expression vectors can be obtained from commercial sources (e.g., Stratagene, La Jolla, Calif).
  • Vector constructs comprising isolated spa sequences can be introduced into cultured mammalian cells by, for example, calcium phosphate-mediated transfection (Wigler et al., Cell 74:725, 1978; Corsaro and Pearson, Somatic Cell Genetics 7:603, 1981; Graham and Van der Eb, Virology 52:456, 1973), electroporation (Neumann et al., EMBO J. 7:841-845, 1982), or DEAE-dextran mediated transfection (Ausubel et al. (eds.), Current Protocols in Molecular Biology, John Wiley and Sons, Inc., NY, 1987). See generally Sambrook et al. (supra).
  • a selectable marker is generally introduced into the cells along with the gene or cDNA of interest.
  • Preferred selectable markers for use in cultured mammalian cells include genes that confer resistance to drugs, such as neomycin. hygromycin, and methotrexate.
  • the selectable marker may be an amplifiable selectable marker.
  • Preferred amplifiable selectable markers are the DHFR gene and the neomycin resistance gene. Selectable markers are reviewed by Thilly (Mammalian Cell Technology, Butterworth Publishers, Stoneham, MA). Mammalian cells containing a suitable vector are allowed to grow for a period of time, typically 1-2 days, to begin expressing the DNA sequence(s) of interest.
  • Drug selection is then applied to select for growth of cells that are expressing the selectable marker in a stable fashion.
  • the drug concentration may be increased in a stepwise manner to select for increased copy number of the cloned sequences, thereby increasing expression levels.
  • Cells expressing the introduced sequences are selected and screened for production of the protein of interest in the desired form or at the desired level. Cells that satisfy these criteria can then be cloned and scaled up for production.
  • baculoviruses as vectors for expressing heterologous DNA sequences in insect cells has been reviewed by Atkinson et al. (Pestic. Sci. 25:215-224,1990).
  • Agrobacterium rhizogenes as vectors for expressing genes in plant cells has been reviewed by Sinkar et al., J. Biosci. (Bangalore) 77:47-58, 1987.
  • the polypeptide or peptide may be preliminarily released and/or isolated from the host cell utilizing methods such as those discussed previously herein.
  • an isolated nucleic acid encoding the polypeptide is introduced into an expression vector comprising a promoter that is active in the host cell.
  • Other components of the expression unit such as transcribed but not translated sequences at the ends of the coding region may also be selected according to the particular host utilized. In some cases, it may be necessary to introduce artificially an intervening sequence to ensure high level expression. Expression can be monitored by SDS-PAGE and staining, if expression levels are sufficiently high.
  • the protein is produced with a tag
  • detection by anti-tag antibody can be carried out and if produced with no tag, detection by anti-Spa antibody that does not recognize homologous proteins of the host may be employed.
  • any method known in the art for protein identification may be utilized to this end (e.g., a high resolution electrophoretic method or 2D electrophoresis).
  • the proteins of the present invention are utilized to prepare antibodies that specifically bind to an epitope present on Spa polypeptides Accordingly, the present invention also provides such antibodies.
  • the antibodies bind to specific opsonic epitopes present on a Spa polypeptide.
  • the antibodies do not bind to epitopes present on M-proteins of a Streptococcus species.
  • the term "antibodies" includes polyclonal antibodies, monoclonal antibodies, anti-idiotypic antibodies, fragments thereof such as F(ab') 2 and Fab fragments, and recombinantly or synthetically produced antibodies.
  • Such antibodies incorporate the variable regions that permit a monoclonal antibody to specifically bind, which means an antibody able to selectively bind to a peptide produced from a spa gene of this invention.
  • the affinity of a monoclonal antibody or antibody can be readily determined by one of ordinary skill in the art (see Scatchard, Ann. N Y. Acad. Sci. 57:660-672, 1949).
  • Polyclonal antibodies can be readily generated by one of ordinary skill in the art from a variety of warm-blooded animals such as horses, cows, goats, sheep, dogs, chickens, turkeys, rabbits, mice, or rats. Briefly, the desired protein or peptide is utilized to immunize the animal through intraperitoneal, intramuscular, intraocular, or subcutaneous injections. The immunogenicity of the protein or peptide of interest may be increased through the use of an adjuvant such as Freund's complete or incomplete adjuvant. Following several booster immunizations, small samples of serum are collected and tested for reactivity to the desired protein or peptide.
  • an adjuvant such as Freund's complete or incomplete adjuvant.
  • polyclonal antisera give a signal that is at least three times greater than background. Once the titer of the animal has reached a plateau in terms of its reactivity to the protein, larger quantities of polyclonal antisera may be readily obtained either by weekly bleedings, or by exsanguinating the animal. Monoclonal antibodies can also be readily generated using well-known techniques (see U.S. Patent Nos.
  • a subject animal such as a rat or mouse is injected with a desired protein or peptide.
  • various techniques may be utilized in order to increase the resultant immune response generated by the protein, in order to develop greater antibody reactivity.
  • the desired protein or peptide may be coupled to another carrier protein such as ovalbumin or keyhole limpet hemocyanin (KLH), or through the use of adjuvants such as Freund's complete or incomplete adjuvant.
  • KLH keyhole limpet hemocyanin
  • the present invention also provides fusion polypeptides or proteins containing a portion of a Spa polypeptide. Fusion proteins are useful for several purposes, including the combining of two or more catalytic functions from separate polypeptide sources, and for raising antibodies to epitopes. For raising antibodies to epitopes, the fusion protein typically contains a peptide epitope of a Spa of at least 8, 10, 15 or 20 amino acids fused to a protein that enhances an immune response to the epitope. A typical protein for this purpose is KLH.
  • another aspect of the present invention provides a non-naturally occurring fusion protein, comprising a first Spa polypeptide segment comprised of at least 8 contiguous amino acids of a Spa polypeptide or variant described above, fused in- frame to a second polypeptide segment. More preferred embodiments include Spa polypeptide segments of at least 10, 15 or 20 amino acids.
  • the second polypeptide segment may optionally comprise another portion of the Spa polypeptide that is not naturally adjacent to the first segment, or comprise sequences from a non-Spa polypeptide.
  • nucleic acids and vectors encoding the aforementioned fusion proteins and host cells carrying the same.
  • carrier proteins,fusion proteins or linkers is particularly advantageous when antibody is to be raised against a peptide antigen carrying an opsonic epitope
  • a synthetic 23 amino acid peptide comprising an N-terminus of a Spa polypeptides was linked to KLH in order to produces antibodies against an opsonic epitope contained within the peptide.
  • suitable carrier proteins include but are not limited to tetanus toxoid, diphtheria toxoid, bovine serum albumin, hen egg lysozyme, gelatin, bovine gamma globulin, B subunit of cholera toxin, B subunit of E.
  • linking a Spa epitope to a carrier protein will usually include an in frame fusion of the peptide through a linker amino acid sequence of at least 2 amino acids in length. More typically the linker is 7 to 35 amino acids, and most typically about 7 to 15 amino acids wherein 2 to 7 of the linker amino acids are hydrophobic amino acids.
  • the initial elicitation of an immune response may preferably be through intraperitoneal, intramuscular, intranasal, oral, or subcutaneous routes. Between one and three weeks after the initial immunization, the animal may be reimmunized. The animal may then be test bled and the serum tested for binding to the desired antigen using assays as described above.
  • Additional immunizations may also be accomplished until the animal has reached a plateau in its reactivity to the desired protein or peptide.
  • the animal may then be given a final boost of the desired protein or peptide, and three to four days later sacrificed.
  • the spleen and lymph nodes may be harvested and disrupted into a single cell suspension by passing the organs through a mesh screen or by rupturing the spleen or lymph node membranes which encapsulate the cells.
  • the red cells are subsequently lysed by the addition of a hypotonic solution, followed by immediate return to isotonicity.
  • suitable cells for preparing monoclonal antibodies are obtained through the use of in vitro immunization techniques. Briefly, an animal is sacrificed, and the spleen and lymph node cells are removed as described above. A single cell suspension is prepared, and the cells are placed into a culture containing a form of the protein or peptide of interest that is suitable for generating an immune response as described above. Subsequently, the lymphocytes are harvested and fused as described below.
  • Cells that are obtained through the use of in vitro immunization or from an immunized animal as described above may be immortalized by transfection with a virus such as the Epstein-Barr Virus (EBV). (See Glasky and Reading, Hybridoma 5(4):377-389, 1989.)
  • EBV Epstein-Barr Virus
  • the harvested spleen and/or lymph node cell suspensions are fused with a suitable myeloma cell in order to create a "hybridoma" which secretes monoclonal antibodies.
  • Suitable myeloma lines are preferably defective in the construction or expression of antibodies, and are additionally syngeneic with the cells from the immunized animal.
  • myeloma cell lines are well known in the art and may be obtained from sources such as the American Type Culture Collection (ATCC), Rockville, Maryland (see Catalogue of Cell Lines & Hybridomas, 6 th ed., ATCC, 1988).
  • Representative myeloma lines include: for humans, UC 729-6 (ATCC No. CRL 8061), MC/CAR-Z2 (ATCC No. CRL 8147), and SKO-007 (ATCC No. CRL 8033); for mice, SP2/0-Agl4 (ATCC No. CRL 1581), and P3X63Ag8 (ATCC No. TIB 9); and for rats, Y3-Agl.2.3 (ATCC No.
  • fusion lines include NS-1 (ATCC No. TIB 18) and P3X63 -Ag 8.653 (ATCC No. CRL 1580), which may be utilized for fusions with either mouse, rat, or human cell lines. Fusion between the myeloma cell line and the cells from the immunized animal can be accomplished by a variety of methods, including the use of polyethylene glycol (PEG) (see Antibodies: A Laboratory Manual. Harlow and Lane, supra) or electrofusion. (See Zimmerman and Vienken, J. Membrane Biol.
  • PEG polyethylene glycol
  • the cells are placed into culture plates containing a suitable medium, such as RPMI 1640 or DMEM (Dulbecco"s Modified Eagles Medium, JRH Biosciences, Lenexa, Kan.).
  • a suitable medium such as RPMI 1640 or DMEM (Dulbecco"s Modified Eagles Medium, JRH Biosciences, Lenexa, Kan.).
  • the medium may also contain additional ingredients, such as Fetal Bovine Serum (FBS, e.g.. from Hyclone, Logan, Utah, or JRH Biosciences), thymocytes that were harvested from a baby animal of the same species as was used for immunization, or agar to solidify the medium.
  • FBS Fetal Bovine Serum
  • the medium should contain a reagent which selectively allows for the growth of fused spleen and myeloma cells.
  • HAT medium hyperxanthine, aminopterin, and thymidine
  • HAT medium hyperxanthine, aminopterin, and thymidine
  • the resulting fused cells or hybridomas may be screened in order to determine the presence of antibodies which recognize the desired antigen.
  • hybridoma producing antibodies that bind to the protein of interest can be isolated.
  • mRNA is isolated from a B cell population and utilized to create heavy and light chain immunoglobulin cDNA expression libraries in the ⁇ IMMUNOZAP(H) and ⁇ MMUNOZAP(L) vectors. These vectors may be screened individually or co-expressed to form Fab fragments or antibodies (see Huse et al.
  • antibodies can also be constructed utilizing recombinant DNA techniques to incorporate the variable regions of a gene that encodes a specifically binding antibody. The construction of these antibodies can be readily accomplished by one of ordinary skill in the art given the disclosure provided herein.
  • DNA segments encoding the desired protein or peptide of interest-specific antigen binding domains are amplified from hybridomas that produce a specifically binding monoclonal antibody, and are inserted directly into the genome of a cell that produces human antibodies. (See Verhoeyen et al. (supra); see also Reichmann et al. (supra)).
  • This technique allows the antigen-binding site of a specifically binding mouse or rat monoclonal antibody to be transferred into a human antibody.
  • Such antibodies are preferable for therapeutic use in humans because they are not as antigenic as rat or mouse antibodies.
  • genes that encode the variable region from a hybridoma producing a monoclonal antibody of interest are amplified using oligonucleotide primers for the variable region.
  • primers for mouse and human variable regions including, among others, primers for V Ha , V H b, V Hc , V Hc j, C H ⁇ , V L and C L regions, are available from Stratagene (La Jolla, Calif).
  • primers may be utilized to amplify heavy or light chain variable regions, which may then be inserted into vectors such as IMMUNOZAPTM(H) or IMMUNOZAPTM(L) (Stratagene), respectively. These vectors may then be introduced into E coli for expression. Utilizing these techniques, large amounts of a single-chain polypeptide containing a fusion of the V H and V L domains may be produced (see Bird et al., Science 242:423-426, 1988).
  • Monoclonal antibodies and other antibodies can be produced in a number of host systems, including tissue cultures, bacteria, eukaryotic cells, plants and other host systems known in the art.
  • antibodies or antibodies may be isolated or purified by many techniques well known to those of ordinary skill in the art (see Antibodies: A Laboratory Manual, Harlow and Lane (supra)). Suitable techniques include peptide or protein affinity columns, HPLC or RP-HPLC, purification on protein A or protein G columns, or any combination of these techniques. Within the context of the present invention, the term "isolated" as used to define antibodies or antibodies means “substantially free of other blood components.”
  • antibodies of the present invention have many uses. For example, antibodies can be utilized in flow cytometry to identify cells bearing such a protein. Briefly, in order to detect the protein or peptide of interest on cells, the cells are incubated with a labeled monoclonal antibody which specifically binds to the protein of interest, followed by detection of the presence of bound antibody. Labels suitable for use within the present invention are well known in the art including, among others, flourescein isothiocyanate (FITC), phycoerythrin (P ⁇ ), horse radish peroxidase (HRP), and colloidal gold.
  • FITC flourescein isothiocyanate
  • P ⁇ phycoerythrin
  • HRP horse radish peroxidase
  • FITC Fluorescein Isothiocyanate to Antibodies.
  • I Experiments on the Conditions of Conjugation," Immunology 75:865-873, 1970.
  • Keltkamp See also Keltkamp, "Conjugation of Fluorescein Isothiocyanate to Antibodies. II. A Reproducible Method," Immunology 75:875-881, 1970; Goding, "Conjugation of Antibodies with Fluorochromes: Modification to the Standard Methods," J. Immunol. Methods 75:215- 226, 1970.
  • the antibodies can also be used to target drugs against Streptococci, to diagnose infection by these bacteria, or for treating an infection caused thereby.
  • Nucleic acid molecules can be used to detect the expression of the spa gene in a biological sample.
  • probe molecules include double-stranded nucleic acid molecules comprising the nucleotide sequence of SEQ ID NOS: l or 4 or a fragment thereof, as well as single-stranded nucleic acid molecules having the complement of the nucleotide sequence of SEQ ID NOS:l or 4 or a fragment thereof.
  • Probe molecules may be DNA, RNA, oligonucleotides, and the like.
  • Preferred probes bind with regions of the spa gene that have a low sequence similarity to comparable regions in other Streptococcal proteins.
  • suitable probes will bind with at least one portion of the nucleotide sequence of SEQ ID NO:l.
  • portion refers to at least eight or more nucleotides.
  • RNA isolated from a biological sample
  • RNA isolated from a biological sample
  • RNA detection includes northern analysis and dot/slot blot hybridization (see, for example, Ausubel (1995) at pages 4-1 to 4-27, and Wu et al. (eds.), "Analysis of Gene Expression at the RNA Level," in Methods in Gene Biotechnology, pages 225-239 (CRC Press, Inc. 1997)).
  • Nucleic acid probes can be detectably labeled with radioisotopes such as 32 P or 3? S.
  • Spa RNA can be detected with a nonradioactive hybridization method (see, for example, Isaac (ed.), Protocols for Nucleic Acid Analysis by Nonradioactive Probes (Humana Press, Inc. 1993)).
  • nonradioactive detection is achieved by enzymatic conversion of chromogenic or chemiluminescent substrates.
  • Illustrative nonradioactive moieties include biotin, fluorescein, and digoxigenin.
  • PCR polymerase chain reaction
  • Standard techniques for performing PCR are well-known (see, generally, Mathew (ed.), Protocols in Human Molecular Genetics (Humana Press, Inc. 1991), White (ed.), PCR Protocols: Current Methods and Applications (Humana Press, Inc. 1993), Cotter (ed.), Molecular Diagnosis of Cancer (Humana Press, Inc. 1996), Hanausek and Walaszek (eds.), Tumor Marker Protocols (Humana Press, Inc. 1998), Lo (ed.), Clinical Applications of PCR (Humana Press, Inc. 1998), and Meltzer (ed.), PCR in Bioanalysis (Humana Press, Inc. 1998)).
  • PCR primers are designed to amplify a portion of the spa gene that has a low sequence similarity to other Streptococcal proteins.
  • primers having the nucleotide sequences of SEQ. ID NOS: 6 and 7 are suitable for amplifying a spa gene from several Streptococci.
  • suitable primers include those designed to amplify portions of a spa gene encoding an immunogenic epitope of SEQ ID NOS: 2 or 5.
  • RT-PCR reverse transcriptase-PCR
  • RNA is isolated from a biological sample, reverse transcribed to cDNA, and the cDNA is incubated with Spa primers (see, for example, Wu et al. (eds.), "Rapid Isolation of Specific cDNAs or Genes by PCR,” in Methods in Gene Biotechnology, pages 15-28 (CRC Press, Inc. 1997)).
  • Spa primers see, for example, Wu et al. (eds.), "Rapid Isolation of Specific cDNAs or Genes by PCR," in Methods in Gene Biotechnology, pages 15-28 (CRC Press, Inc. 1997).
  • a biological sample is obtained from a sample for RNA preparation. If the test material contains a variety of biological materials, then the sample may be layered onto a Ficoll-Hypaque density gradient and centrifuged in order to separate some of the biological materials.
  • RNA may then be isolated from the sample using, for example, the gunadinium-thiocyanate cell lysis procedure described above.
  • a solid- phase technique can be used to isolate mRNA from a cell lysate.
  • a reverse transcription reaction can be primed with the isolated RNA using random oligonucleotides, short homopolymers of dT, or Spa antisense oligomers.
  • Oligo-dT primers offer the advantage that various mRNA nucleotide sequences are amplified that can provide control target sequences. Spa sequences are amplified by the polymerase chain reaction using two flanking oligonucleotide primers that are typically 20 bases in length.
  • PCR amplification products can be detected using a variety of approaches.
  • PCR products can be fractionated by gel electrophoresis, and visualized by ethidium bromide staining.
  • fractionated PCR products can be transferred to a membrane, hybridized with a detectably-labeled Spa probe, and examined by autoradiography.
  • Additional alternative approaches include the use of digoxigenin-labeled deoxyribonucleic acid triphosphates to provide chemiluminescence detection, and the C-TRAK colorimetric assay.
  • CPT cycling probe technology
  • NASBA nucleic acid sequence-based amplification
  • CATCH cooperative amplification of templates by cross-hybridization
  • LCR ligase chain reaction
  • kits for performing a diagnostic assay for spa gene expression comprise nucleic acid probes comprising a portion of the nucleotide sequence of S ⁇ Q ID NOS:l or 4, or a fragment thereof, or nucleic acids encoding a peptide according to S ⁇ Q. ID NOS: 2, 3 or 5 or fragments thereof.
  • Probe molecules may be DNA, RNA, oligonucleotides, and the like.
  • Kits may comprise nucleic acid primers for performing PCR.
  • kits contains all the necessary elements to perform a nucleic acid diagnostic assay described above.
  • a kit will comprise one or more containers, in which one container comprises a Spa probe or primer, and a second container comprises one or more reagents capable of indicating the presence of Spa sequences. Examples of such indicator reagents include detectable labels such as radioactive labels, fluorochromes, chemiluminescent agents, and the like.
  • a kit will also comprise written material describing the use of such Spa probes and primers for detection of spa gene expression. The written material can be applied directly to a container, or the written material can be provided in the form of a packaging insert.
  • the present invention further contemplates the use of anti-Spa antibodies to screen biological samples in vitro for the presence of Spa.
  • anti-Spa antibodies are used in liquid phase.
  • the presence of Spa in a biological sample can be tested by mixing the biological sample with a trace amount of labeled Spa and an anti-Spa antibody under conditions that promote binding between Spa and its antibody.
  • Complexes of Spa and anti-Spa in the sample can be separated from the reaction mixture by contacting the complex with an immobilized protein which binds with the antibody, such as an Fc antibody or Staphylococcus protein A.
  • the concentration of Spa in the biological sample will be inversely proportional to the amount of labeled Spa bound to the antibody and directly related to the amount of free labeled Spa.
  • in vitro assays can be performed in which anti-Spa antibody is bound to a solid-phase carrier.
  • antibody can be attached to a polymer, such as aminodextran, in order to link the antibody to an insoluble support such as a polymer-coated bead, a plate or a tube.
  • polymer such as aminodextran
  • Immunochemical detection can be performed by contacting a biological sample with an anti-Spa antibody, and then contacting the biological sample with a detectably labeled molecule which binds to the antibody.
  • the detectably labeled molecule can comprise an antibody moiety that binds to anti-Spa antibody.
  • the anti-Spa antibody can be conjugated with avidin/streptavidin (or biotin) and the detectably labeled molecule can comprise biotin (or avidin/streptavidin). Numerous variations of this basic technique are well-known to those of skill in the art.
  • an anti-Spa antibody can be conjugated with a detectable label to form an anti-Spa immunoconjugate.
  • Suitable detectable labels include, for example, a radioisotope, a fluorescent label, a chemiluminescent label, an enzyme label, a bioluminescent label or colloidal gold. Methods of making and detecting such detectably-labeled immunoconjugates are well-known to those of ordinary skill in the art, and are described in more detail below.
  • the detectable label can be a radioisotope that is detected by autoradiography.
  • Isotopes that are particularly useful for the purpose of the present invention are 3 H, I25 I, 131 1, 35 S and 14 C.
  • Anti-Spa immunoconjugates can also be labeled with a fluorescent compound.
  • the presence of a fluorescently-labeled antibody is determined by exposing the immunoconjugate to light of the proper wavelength and detecting the resultant fluorescence.
  • Fluorescent labeling compounds include fluorescein isothiocyanate, rhodamine, phycoerytherin, phycocyanin, allophycocyanin, o-phthaldehyde and fluorescamine.
  • anti-Spa immunoconjugates can be detectably labeled by coupling an antibody component to a chemiluminescent compound.
  • the presence of the chemiluminescent-tagged immunoconjugate is determined by detecting the presence of luminescence that arises during the course of a chemical reaction.
  • chemiluminescent labeling compounds include luminol, isoluminol, an aromatic acridinium ester, an imidazole, an acridinium salt and an oxalate ester.
  • Bioluminescent compound can be used to label anti-Spa immunoconjugates of the present invention.
  • Bioluminescence is a type of chemiluminescence found in biological systems in which a catalytic protein increases the efficiency of the chemiluminescent reaction. The presence of a bioluminescent protein is determined by detecting the presence of luminescence.
  • Bioluminescent compounds that are useful for labeling include luciferin, luciferase and aequorin.
  • anti-Spa immunoconjugates can be detectably labeled by linking an anti-Spa antibody component to an enzyme.
  • the enzyme moiety reacts with the substrate to produce a chemical moiety which can be detected, for example, by spectrophotometric, fluorometric or visual means.
  • enzymes that can be used to detectably label polyspecific immunoconjugates include ⁇ - galactosidase, glucose oxidase, peroxidase and alkaline phosphatase.
  • the convenience and versatility of immunochemical detection can be enhanced by using anti-Spa antibodies that have been conjugated with avidin, streptavidin, and biotin (see, for example, Wilchek et al. (eds.), “Avidin-Biotin Technology,” Methods In Enzymology, Vol. 184 (Academic Press 1990), and Bayer et al., "Immunochemical Applications of Avidin-Biotin Technology,” in Methods In Molecular Biology, Vol. 10, Manson (ed.), pages 149-162 (The Humana Press, Inc. 1992).
  • kits for performing an immunological diagnostic assay for spa genes comprise one or more containers, in which one container comprises an anti-Spa antibody, or antibody fragment.
  • a second container may comprise one or more reagents capable of indicating the presence of Spa antibody or antibody fragments. Examples of such indicator reagents include detectable labels such as a radioactive label, a fluorescent label, a chemiluminescent label, an enzyme label, a bioluminescent label, colloidal gold, and the like.
  • a kit will also comprise written material describing the use of Spa antibodies and antibody fragments for detection of Spa protein. The written material can be applied directly to a container, or the written material can be provided in the form of a packaging insert.
  • a new protective antigen of group A Streptococci enables another aspect of this invention which is the provision of therapeutic compositions to protect against infections caused by group A Streptococci.
  • protecting against infections means to prevent, reduce the likelihood of, or ameliorate the pathogenic effects of, an infection caused by a Streptococcus
  • isolated Spa antigens of the this invention are formulated in a therapeutically suitable medium and used to elicit cross-protective antibodies in an animal.
  • Spa antigens include the aforementioned proteins, polypeptides or peptides whether naturally occurring, synthetic, or produced by expression of a recombinant DNA vector containing a nucleic acid sequence encoding a Spa antigen, which are reactive with antibodies raised against the purified Spa protein or peptides of the present invention.
  • the therapeutic composition containing a Spa antigen comprises an antigen that is protective against a multiple Streptococci serotypes.
  • the therapeutic composition contains an opsonic epitope that is cross protective against group A Streptococci including Type 28, Type 3, Type 18 Streptococci.
  • Such a composition is expected to be considerably less complex than previous compositions comprised of M-protein or derivative thereof, for example, compositions where limited amino-terminal fragments of different M proteins are linked in tandem to evoke protective immune responses against each serotype represented in the vaccine. While such an approach has the advantage of limiting the amount of M protein contained in a vaccine, a large number of combinations must be provided because each M protein fragment is type-specific.
  • Spa antigens and antibodies, and nucleic acids of the present invention can be used to provide broad protection and/or can be used in combination with M-proteins and peptides to enhance the effectiveness of protection provided by either protein alone.
  • compositions and methods comprising one or more of the above-described Spa antigens or antibodies thereto in combination with one or more pharmaceutically or physiologically acceptable carriers, adjuvants, binders or diluents.
  • Compositions containing antigens can be used to elicit or enhance an immune response in a recipient animal, which is preferably a human being, and preferably elicits or enhances a protective or partially protective immunity against Streptococcus, or against a host cell expressing a surface antigen comprised of a Spa antigen of the present invention.
  • Compositions containing antibodies may be used to diagnose or treat infections caused by Streptococci.
  • such carriers, adjuvants, binders or diluents are nontoxic to recipients at the dosages and concentrations employed.
  • the preparation of such compositions entails combining the an antigen or antibody of this invention with buffers, antioxidants such as ascorbic acid, low molecular weight (less than about 10 residues) polypeptides, proteins, amino acids, carbohydrates including glucose, sucrose or dextrins, chelating agents such as EDTA, glutathione and other stabilizers and excipients.
  • Neutral buffered saline or saline mixed with nonspecific serum albumin are exemplary appropriate diluents.
  • adjuvants include alum or aluminum hydroxide for humans. It will be evident in light of the present specification to those in the art that the amount and frequency of administration can be optimized in clinical trials, and will depend upon such factors as the disease or disorder to be treated, the degree of immune inducement, enhancement, or protection required, and many other factors.
  • the therapeutic composition is administered orally, and a Spa antigen of the invention is taken up by cells, such as cells located in the lumen of the gut.
  • the therapeutic composition can be parenterally administrated via the subcutaneous route, or via other parenteral routes.
  • Other routes include buccal/sublingual, rectal, nasal, topical (such as transdermal and ophthalmic), vaginal, pulmonary, intraarterial, intramuscular, intraperitoneal, intraocular, intranasal or intravenous, or indirectly.
  • the Spa compositions of the present invention can be prepared and administered as a liquid solution, or prepared as a solid form (e.g., lyophilized) which can be administered in solid form or resuspended in a solution in conjunction with administration.
  • quantities of Spa antigen in the composition will vary generally from about 0.1 ⁇ g to 1000 mg, typically from about 1 ⁇ WOO ⁇ /37648 PCTVUS99/30807
  • Booster immunizations can be given at 2-6 weeks intervals.
  • the Spa antigens of this invention may also be used with immunological carriers in conjugate vaccines.
  • a beneficial carrier includes another polypeptide that is has immunostimulent but does not have immunosuppressive effects. Such carriers may be used to elicit an increased immune response to the conjugated molecule.
  • the spa gene products of this invention may also be used as carriers (in conjugates or fusion proteins) in combination with other antigens so as to provide compositions providing further protection elicited by epitopes additional to those contained on Spa, for example, M protein polypeptides may.
  • a further aspect of the present invention is protection from Streptococcus infections by treatment of an animal, preferably an animal and most preferably a human with a therapeutic composition containing the Spa antigens or antibodies of the present invention.
  • “protection” means to prevent or to reduce the severity of a disease associated with a Streptococcus infection.
  • the Spa antigens of the present invention provide protection against multiple serotypes of Streptococci. In one embodiment, protection is provided against multiple stereotypes of group A Streptococci.
  • Table 5 (Example 6) where it is shown that a composition comprised of crude surface peptides containing a Spa polypeptide or an isolated Spa polypeptide from a Type 18 Streptococci elicited production of antisera that provided opsonic protection against Type 3, Type 18 and Type 28 Streptococci.
  • Tables 3 and 4 (Example 5) show that antisera raised against the 23 amino acid N terminus of a Spa polypeptide displayed similar opsonization and bactericidal activity TO antisera against the crude peptides and isolated Spa polypeptides.
  • another aspect of the present invention is therapeutic methods for protecting an animal against a Streptococcus infection that includes the step of administering to the animal at least one of the aforementioned therapeutic compositions.
  • administering a therapeutic compositions containing Spa antigens elicits opsonic antibodies in the animal.
  • administering a composition containing antibodies raised against Spa antigens will provide opsonic antibodies which facilitate a phagocytic responses in the animal.
  • protection is provided against multiple serotypes of Streptococcus.
  • the therapeutic composition is administered by at least one of oral administration, intranasal administration, intramuscular vaccination, subcutaneous vaccination, or vascular vaccination.
  • the therapeutic method is used with the human.
  • compositions and methodologies described herein are suitable for a variety of uses. To this end, the following examples are presented for purposes of illustration, not limitation.
  • the parent Type 18 Streptococcal strain 87-282 was obtained from Dr. P. Patrick Cleary at the University of Minnesota.
  • the M3 strain (3375) was provided by Dr. James Musser, Baylor College of Medicine, Houston, TX.
  • the M28 strain (S2356) was from our laboratory collection.
  • the new Streptococcal protective antigen was discovered during studies of an M-negative mutant of Type 18 Streptococci. Briefly, as discussed in more detail below, the M-negative Ml 8 strain was constructed by interrupting the emml8 gene with an ⁇ -element. Southern blot analyses of chromosomal DNA from the Ml 8 and M18 ⁇ strains that was probed with (Km2 and emml8 fragments and PCR analyses using primers from the emm gene and the ⁇ -element revealed that there was a single copy of the ⁇ -element inserted -140 bp beyond the start codon of the emm 18 gene. ⁇ VO d ⁇ /37648 PCT/US99/30807
  • a fragment of the emml8 gene was initially cloned by PCR using a forward primer that copied the 3' end of the emm 18 gene and a reverse primer that was specific for this subfamily (SF 3) of emm-like genes.
  • the purified PCR product was ligated into pKK223-3 and the insert was sequenced by standard methods.
  • the intact emml8 gene was later cloned using a reverse primer that copied the 5' end of the scpA gene and the purified PCR product was ligated into pQE-30 (Qiagen, Chatsworth, CA).
  • the recombinant Emm 18 protein was purified by affinity chromatography over a nickel column according to the instructions provided by Qiagen.
  • Insertion of the ⁇ -interposon into emml8 and transformation of Type 18 Streptococci was accomplished essentially as previously described for Type 24 Streptococci. Briefly, emml8 was ligated into pKK223-3 and then cut with Xhol, which recognizes a single site between bases 136 and 141 of the emm 18 gene. The ends were repaired with Klenow fragment. Plasmid pBR322- ⁇ ,Km2 was digested with Smal and the ⁇ ,Km2 fragment was purified from a 0.8% agarose gel and ligated into the cut emmlS gene. The resulting plasmid, pKKM18 ⁇ , was electroporated into Type 18 Streptococci. One kanamycin-resistant colony, designated M18 ⁇ , was selected for further study.
  • Streptococcal chromosomal DNA was digested with BsaH I and electrophoresed in a 1%> agarose gel. The DNA fragments were transferred to a nylon membrane (Sigma) and probed with digoxigenin-labeled (Km2 fragment or emml8 according to instructions provided by the manufacturer (Boehringer Mannheim, Indianapolis, IN).
  • EXAMPLE 2 GROWTH IN BLOOD AND MOUSE VIRULENCE OF Ml 8 AND Ml 8 ⁇ A. Growth in non-immune human blood.
  • the virulence of the M- negative mutant of Type 18 Streptococci was first assessed by its ability to grow in nonimmune human blood (Table 1). Streptococci were grown to early log-phase in Todd-Hewitt broth and the inoculum indicated was added to 0.45 ml normal, heparinized human blood that did not contain Ml 8 antibodies. The mixture was rotated end-over-end at 37°C for 3 hr. Organisms surviving were quantitated on pour plates of sheep's blood agar using an aliquot of the mixture. The parent strain of Ml 8 grew to just over 8 generations after a three-hour rotation in blood. The M18 ⁇ mutant grew to approximately 7.5 generations in the same assay. Table 1. Growth in human blood of M18 and M18 ⁇ Streptococci.
  • Intraperitoneal challenge infections The most stringent laboratory assay for virulence is intraperitoneal challenge infections of nonimmune mice. Briefly, four groups of six Swiss white mice each were challenged with 10-fold increasing inocula, ranging from 2.7xl0 4 to 2.7xl0 7 CFU of either M18 or Ml 8 ⁇ . Deaths were recorded for seven days following challenge infections. The LD50 was determined by the method of Reed and Muench after using 10-fold increasing doses of each organism. The LD50 of the parent M18 strain was 0.73xl0 5 and of the M18 ⁇ was 1.26xl0 5 . Of 24 mice challenged with each organism, 8 challenged with Ml 8 died while 7 challenged with M18 ⁇ died.
  • Organisms recovered from the spleens of mice that succumbed to challenge infections with M18 ⁇ were kanamycin-resistant and Ml 8 negative, indicating that there was no reversion to the parent phenotype in vivo. These results demonstrated that the expression of Ml 8 was not required for virulence of Type 18 Streptococci.
  • test antisera The bactericidal activity of test antisera was determined using a similar assay except that fewer Streptococci were added to the mixture, which was rotated for 3 hr. at 37°C. At the end of the rotation, 0.1 ml aliquots were added to sheep blood agar and pour plates were made to quantitate viable bacteria. Results shown in Table 2 below are from one representative experiment. Briefly, only the Ml 8 parent strain was opsonized by antisera against SM18(l-30) or recombinant M18. The association of M18 ⁇ with PMNs remained at baseline levels in the presence of both of these antisera.
  • peptide fragments from the surface of M18 ⁇ were extracted using dilute solutions of pepsin at suboptimal pH.
  • the extract was precipitated in 60% saturated ammonium sulfate, dialyzed extensively against distilled water, and then lyophilized.
  • the mixture of surface proteins and peptides is referred to as crude pep M18 ⁇ .
  • Example 3 Spa was identified in the crude pepsin extract by opsonization inhibition assays.
  • the crude pep M18 ⁇ was separated by SDS-PAGE on a preparative 10%> gel using reducing conditions. The entire gel was electroblotted to nitrocellulose paper and each end was cut vertically and stained with Coomassie blue. The center section of the nitrocellulose paper was cut into horizontal strips approximately 8-10mm in width. Each strip was then used to absorb rabbit antiserum raised against the crude pep M18 ⁇ for 2 hours at 37°C. One section of the nitrocellulose paper was western blotted with pep M18 ⁇ antiserum to identify immunoreactive bands.
  • the pep M18 ⁇ extract contained a protein with an apparent M.W. of 24kDa (Spa) that absorbed the majority of the opsonic antibodies in the pep Ml 8 ⁇ antiserum ( Figure 2).
  • Opsonization assays were performed using absorbed serum samples and unabsorbed serum, as described above in Example 3. Once the opsonic-inhibitory peptide had been identified in the crude pepsin extract, it was purified by ammonium sulfate precipitation and preparative gel electrophoresis (Prep Cell, model 491, Bio- Rad, Richmond, CA).
  • the purified Spa migrated as a single band, as assessed by SDS-PAGE, with a M.W. of 24kDa ( Figure 3, Lane B).
  • the purified Spa protein was electrophoretically transferred to a PVDF membrane and submitted to the Protein and Nucleic Acid Facility, Beckman Center, Stanford University Medical Center for N- terminal sequencing by Edman degradation. The sequence of an internal peptide of Spa was also determined in the Stanford University Facility.
  • the intact protein on PVDF was digested with LysC protease, 0.25 (mol/ml, at 37°C overnight).
  • the resultant peptides were purified by HPLC on a Vydac C18 column. Selected fractions were assessed for purity by mass spectroscopy and one peptide with a mass of 1249 Daltons was selected for N-terminal sequencing.
  • an internal peptide purified from a LysC digest of the purified Spa contained the amino-terminal sequence:
  • a peptide, S-5p ⁇ 75(l-23)C, copying the N-terminal 23 amino acids of the purified 24 kDa fragment was chemically synthesized.
  • the peptide was covalently linked to KLH and three rabbits were immunized with 100 ⁇ g doses using the same schedule described above.
  • Anti-Spa rabbit antiserum against the purified Streptococcal protective antigen
  • anti-S-Spa(l-23)C rabbit antiserum against a synthetic peptide that copied the N-terminal 23 amino acids of Spa linked to KLH
  • anti-rM18 rabbit antiserum against intact, recombinant Type 18 M protein were used. Details of the assay are provided in Example 3. Experiments were repeated at least three times with similar results. Data presented are from one representative experiment. Briefly, serum from all three rabbits opsonized both the parent and M18 ⁇ strains of group A Streptococci (Table 3), confirming the presence of opsonic epitopes within this limited region of Spa.
  • the antiserum against the synthetic peptide of Spa was also used to identify the native protein in phage lysin extracts of M18 ⁇ .
  • the S-S/? ⁇ 7 (l-23)C antiserum reacted with a single protein in the lysin extract with an apparent M.W. of 50kDa ( Figure 3D), suggesting that the pepsin-derived Spa was a fragment of the larger native protein.
  • Inoculum 21 Inoculum: 32
  • Serotypes tested that were not opsonized by either antiserum were Ml, M2, M5, M6, Ml 3, Ml 4, Ml 9, and M24, all of which were from our laboratory collection.
  • the anti-S-S/? ⁇ 75(l-23)C antisera did not opsonize Types 3 or 28 Streptococci, indicating that this limited region of Spa does not contain cross- opsonic epitopes.
  • a fragment of the spa 18 gene was cloned using PCR and degenerate inosine-containing oligonucleotide primers based on the N-terminal peptide sequence and the sequence of an internal peptide purified from a LysC digest of Spa.
  • the forward set of primers derived from the N-terminal sequence of Spa from amino acid residues 7-1 1 contained the sequence GAR GTI GCI GAY CC (SEQ. ID NO: 6)
  • the reverse primers, from the N-terminal sequence of the internal peptide contained the sequences RTG IGA YTC RCT RTC and RTG RCT YTC IGA RTC (SEQ. ID NO: 7).
  • Nucleotide abbreviations are according to the UUP AC code for nucleic acids.
  • PCR was performed as previously described using the chromosomal DNA from Type 18 Streptococci as the template.
  • the forward primer in combination with the second reverse primer listed above resulted in a single PCR product of 336 bp, which was ligated into pCR2.1 -TOPO (Invitrogen, Carlsbad, CA).
  • DNA sequencing was performed by automated techniques in the University of Tennessee Molecular Resources Center using primers from the 5' and 3' flanking ends of the plasmid. The identity of the spa sequence was confirmed by comparing the translated DNA sequence to the amino acid sequence of Spa that was not used to construct the degenerate PCR primers.
  • the 336 bp PCR product and the translated amino acid sequence contained residues 12-23 of the sequence derived from the Spa protein ( Figure 4), confirming that the DNA was a fragment of spal8.
  • a search of the current entries in GenBank and the Type 1 Streptococcal genome sequence data base revealed that the spal8 gene fragment did not share sequence homology with any known proteins, suggesting that Spa is a new protective antigen of group A Streptococci.
  • Standard molecular biology techniques were used to obtain a full-length cDNA encoding a spa protein.
  • the sequences for the full-length cDNA and encoded protein are depicted in Figures 5 and 6, respectively.
  • the full-length protein includes a 37 residue signal peptide that is cleaved to form a mature spa polypeptide having the same N-terminus as the 23 residue peptide identified as SEQ ID NO:3.

Abstract

La présente invention concerne la découverte d'un nouvel antigène protecteur de Streptococcus (désigné sous le nom de Spa) qui a été identifié et isolé des Streptococci. Le Spa est un antigène de surface distinct de la protéine M qui évoque des anticorps opsoniques qui servent de protection contre de multiples sérotypes de streptococci. L'invention concerne également des polypeptides, des protéines, des peptides Spa isolés, et des anticorps contre ces derniers, ainsi que des acides nucléiques codant les antigènes peptides et polypeptides Spa. L'invention concerne en outre des méthodes d'identification et d'isolement d'un polypeptide Spa, des compositions thérapeutiques comprenant des antigènes ou des anticorps Spa et des méthodes d'utilisation de ces derniers visant à protéger un animal contre une infection de Streptococcus.
EP99967585A 1998-12-22 1999-12-22 Antigene protecteur de streptococci de groupe a (spa) Withdrawn EP1141311A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US11379498P 1998-12-22 1998-12-22
US113794P 1998-12-22
US11473098P 1998-12-31 1998-12-31
US114730P 1998-12-31
PCT/US1999/030807 WO2000037648A1 (fr) 1998-12-22 1999-12-22 Antigene protecteur de streptococci de groupe a (spa)

Publications (1)

Publication Number Publication Date
EP1141311A1 true EP1141311A1 (fr) 2001-10-10

Family

ID=26811487

Family Applications (1)

Application Number Title Priority Date Filing Date
EP99967585A Withdrawn EP1141311A1 (fr) 1998-12-22 1999-12-22 Antigene protecteur de streptococci de groupe a (spa)

Country Status (5)

Country Link
EP (1) EP1141311A1 (fr)
JP (1) JP2002533084A (fr)
AU (1) AU762100B2 (fr)
CA (1) CA2353802C (fr)
WO (1) WO2000037648A1 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6716433B1 (en) 1997-09-12 2004-04-06 University Of Tennessee Research Foundation Group a streptococcal vaccines
WO2003060143A2 (fr) 2001-10-26 2003-07-24 Id Biomedical Corporation Of Washington Systeme d'expression de proteine efficace
US7255867B2 (en) 2002-11-15 2007-08-14 Id Biomedical Corporation Of Quebec Vaccine
EP3616781A1 (fr) 2003-04-10 2020-03-04 President and Fellows of Harvard College Formation et régulation d'espèces fluidiques
CN104069784B (zh) 2003-08-27 2017-01-11 哈佛大学 流体物种的电子控制
JP2009542196A (ja) * 2006-07-07 2009-12-03 インターセル アーゲー 小型の化膿連鎖球菌抗原およびそれらの使用
EP2356135B1 (fr) 2008-11-05 2017-10-25 Wyeth LLC Composition immunogène à multiples composants pour la prévention d'une maladie streptococcique bêta-hémolytique (bhs)
WO2012174455A2 (fr) 2011-06-17 2012-12-20 University Of Tennessee Research Foundation Vaccin multivalent contre un streptocoque du groupe a
AU2014214613A1 (en) 2013-02-11 2015-08-13 University Of Tennessee Research Foundation Group A streptococcal M-related proteins and methods of use

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994006421A1 (fr) * 1992-09-16 1994-03-31 The University Of Tennessee Research Corporation Vaccin a proteine m multivalente recombinee
AU5128593A (en) * 1992-09-16 1994-04-12 University Of Tennessee Research Corporation, The Antigen of hybrid m protein and carrier for group a streptococcal vaccine
IES960488A2 (en) * 1996-07-03 1997-11-19 Trinity College Dublin Subunit Vaccine for Streptococcus Equi

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO0037648A1 *

Also Published As

Publication number Publication date
CA2353802A1 (fr) 2000-06-29
WO2000037648A1 (fr) 2000-06-29
AU2384600A (en) 2000-07-12
JP2002533084A (ja) 2002-10-08
AU762100B2 (en) 2003-06-19
CA2353802C (fr) 2013-10-01

Similar Documents

Publication Publication Date Title
US20070098737A1 (en) Streptococcal streptolysin S vaccines
US7262024B2 (en) Streptococcus antigens
KR101078919B1 (ko) 신규한 스트렙토코커스 항원
AU2001270381B2 (en) Streptococcus antigens
US20060039922A1 (en) Streptococcal heat shock proteins of the Hsp60 family
US20060246083A1 (en) Protective antigen of group a streptococci
JPH11514217A (ja) 結核の診断のための化合物および方法
US20070122434A1 (en) Heat shock genes and proteins from Neisseria meningitidis, Candida glabrata and Aspergillus fumigatus
KR19990022742A (ko) 스트렙토코커스 속 유래의 hsp70 계열의 쇼크 단백질
US7160547B2 (en) Streptococcal streptolysin S vaccines
AU762100B2 (en) Protective antigen of group A Streptococci (SPA)
JPH09502604A (ja) Ｃａｍｐｙｌｏｂａｃｔｅｒｊｅｊｕｎｉ抗原、並びにそれらの製造及び利用
EP0871734B1 (fr) Fragments polypeptidiques capables de concurrencer l'antigene i/ii de streptococcus mutans
CA2265523A1 (fr) Acide nucleique et sequences d'acides amines relatifs a helicobacter pylori, et compositions de vaccins les contenant
US20100330070A1 (en) Methods Of Making An Antibody And Compositions Thereof
Hong et al. Purification and characterization of M3 protein expressed on the surface of group A streptococcal type 3 strain C203
AU772898B2 (en) Streptococcal ABC transporter protein
US20040151737A1 (en) Streptococcal serum opacity factors and fibronectin-binding proteins and peptides thereof for the treatment and detection of streptococcal infection
CA2470421A1 (fr) Utilisation de nouvelle proteine protease de surface cellulaire du groupe streptococcus (gbs), appelee cspa, comme vaccin destine a prevenir l'infection par le gbs.
EP1712629A2 (fr) Composés et procédés pour le diagnostic de la tuberculose
MXPA97009557A (en) Members of streptococal thermal shock proteins of the hs family
CA2296869A1 (fr) Une lipoproteine a surface exposee de campylobacter jejuni participant a l'adhesion aux cellules hep-2

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20010710

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI

17Q First examination report despatched

Effective date: 20041122

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: THE UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION

17Q First examination report despatched

Effective date: 20041122

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20090818